



---

# MMWR<sup>TM</sup>

## Morbidity and Mortality Weekly Report

[www.cdc.gov/mmwr](http://www.cdc.gov/mmwr)

---

Surveillance Summaries

September 5, 2008 / Vol. 57 / No. SS-8

---

**Surveillance for Cancers Associated  
with Tobacco Use — United States,  
1999–2004**

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**Suggested Citation:** Centers for Disease Control and Prevention. [Title]. Surveillance Summaries, [Date]. MMWR 2008;57(No. SS-#).

### Centers for Disease Control and Prevention

Julie L. Gerberding, MD, MPH  
*Director*

Tanja Popovic, MD, PhD  
*Chief Science Officer*

James W. Stephens, PhD  
*Associate Director for Science*

Steven L. Solomon, MD  
*Director, Coordinating Center for Health Information and Service*

Jay M. Bernhardt, PhD, MPH  
*Director, National Center for Health Marketing*

Katherine L. Daniel, PhD  
*Deputy Director, National Center for Health Marketing*

### Editorial and Production Staff

Frederic E. Shaw, MD, JD  
*Editor, MMWR Series*

Susan F. Davis, MD  
*(Acting) Assistant Editor, MMWR Series*

Teresa F. Rutledge  
*Managing Editor, MMWR Series*

David C. Johnson  
*(Acting) Lead Technical Writer-Editor*

Catherine B. Lansdowne, MS  
*Project Editor*

Peter M. Jenkins  
*(Acting) Lead Visual Information Specialist*

Malbea A. LaPete  
Stephen R. Spriggs  
*Visual Information Specialists*

Kim L. Bright, MBA  
Quang M. Doan, MBA  
Erica R. Shaver  
*Information Technology Specialists*

### Editorial Board

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman  
Virginia A. Caine, MD, Indianapolis, IN  
David W. Fleming, MD, Seattle, WA  
William E. Halperin, MD, DrPH, MPH, Newark, NJ  
Margaret A. Hamburg, MD, Washington, DC  
King K. Holmes, MD, PhD, Seattle, WA  
Deborah Holtzman, PhD, Atlanta, GA  
John K. Iglehart, Bethesda, MD  
Dennis G. Maki, MD, Madison, WI  
Sue Mallonee, MPH, Oklahoma City, OK  
Patricia Quinlisk, MD, MPH, Des Moines, IA  
Patrick L. Remington, MD, MPH, Madison, WI  
Barbara K. Rimer, DrPH, Chapel Hill, NC  
John V. Rullan, MD, MPH, San Juan, PR  
William Schaffner, MD, Nashville, TN  
Anne Schuchat, MD, Atlanta, GA  
Dixie E. Snider, MD, MPH, Atlanta, GA  
John W. Ward, MD, Atlanta, GA

## CONTENTS

Introduction .....	2
Methods .....	2
Results .....	3
Discussion .....	6
References .....	11

## Surveillance for Cancers Associated with Tobacco Use — United States, 1999–2004

Sherri L. Stewart, PhD<sup>1</sup>  
Cheryll J. Cardinez, MSPH<sup>1</sup>  
Lisa C. Richardson, MD<sup>1</sup>  
Leslie Norman<sup>2</sup>  
Rachel Kaufmann, PhD<sup>2</sup>  
Terry F. Pechacek, PhD<sup>2</sup>  
Trevor D. Thompson<sup>1</sup>  
Hannah K. Weir, PhD<sup>1</sup>  
Susan A. Sabatino, MD<sup>1</sup>

<sup>1</sup>*Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion*

<sup>2</sup>*Office on Smoking and Health, National Center for Chronic Disease Prevention and Health Promotion*

### Abstract

**Problem/Condition:** Tobacco use is the leading preventable cause of disease and premature death in the United States. The 2004 Surgeon General report found convincing evidence for a direct causal relationship between tobacco use and the following cancers: lung and bronchial, laryngeal, oral cavity and pharyngeal, esophageal, stomach, pancreatic, kidney and renal pelvis, urinary bladder, and cervical cancers and acute myelogenous leukemia (AML). This report provides state-level cancer incidence data and recent trends for cancers associated with tobacco use. Because information on tobacco use was not available in the databases of the National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology, and End Results (SEER) program, cases of cancer included in this report might or might not be in persons who used tobacco; however, the cancer types included in this report are those defined by the U.S. Surgeon General as having a direct causal relationship with tobacco use (i.e., referred to as tobacco-related cancer in this report). These data are important for initiation, monitoring, and evaluation of targeted tobacco prevention and control measures.

**Reporting Period Covered:** 1999–2004.

**Description of Systems:** Data were obtained from cancer registries affiliated with CDC's NPCR and the National Cancer Institute's SEER program; combined, these data cover approximately 92% of the U.S. population. Combined data from the NPCR and SEER programs provide the best source of information on population-based cancer incidence for the nation and are the only source of information for 41 states (including the District of Columbia) with cancer surveillance programs that are funded solely by NPCR. This report provides age-adjusted cancer incidence rates by demographic and geographic characteristics, percentage distributions for tumor characteristics, and trends in cancer incidence by sex.

**Results:** Approximately 2.4 million cases of tobacco-related cancer were diagnosed during 1999–2004. Age-adjusted incidence rates ranged from 4.0 per 100,000 persons (for AML) to 69.4 (for lung and bronchial cancer). High rates occurred among men, black and non-Hispanic populations, and older adults. Higher incidence rates of lung and laryngeal cancer occurred in the South compared with other regions, particularly the West, consistent with high smoking patterns in the South.

**Interpretation:** The high rates of tobacco-related cancer observed among men, blacks, non-Hispanics, and older adults reflect overall demographic patterns of cancer incidence in the United States and reflect patterns of tobacco use.

**Public Health Action:** The findings in this report emphasize the need for ongoing surveillance and reporting to monitor cancer incidence trends, identify populations at greatest risk for developing cancer related to tobacco use, and evaluate the effectiveness of targeted tobacco control programs and policies.

**Corresponding author:** Sherri L. Stewart, PhD, 4770 Buford Highway, N.E., MS K-57, Atlanta, GA 30341; Telephone: 770-488-4616; Fax: 770-488-4335; E-mail: sstewart2@cdc.gov.

## Introduction

Tobacco use is the leading preventable cause of disease and premature death in the United States, resulting in an estimated 438,000 premature deaths annually, or nearly one of every five deaths each year (1). This estimate includes approximately 38,000 deaths attributed to exposure to secondhand smoke (1), which contains at least 250 chemicals known to be toxic (2). Forms of tobacco used in the United States include cigarettes, cigars, pipes, nonconventional imported cigarettes (e.g., bidis and kreteks [clove cigarettes]), and smokeless tobacco (i.e., snuff or chewing tobacco) (3). Tobacco use causes more deaths each year than alcohol use, car crashes, suicide, acquired immunodeficiency syndrome (AIDS), homicide, and illegal drug use combined (1,4). In addition, smoking accounts for \$167 billion annually in health care expenditures and productivity losses (1).

In the 1950s, the epidemiologic evidence of an association between smoking and lung cancer began to emerge, signaling one of the first warnings of smoking as a cause of cancer and other diseases (5,6). In a landmark report by Surgeon General Luther L. Terry's committee in 1964, the relationship between smoking and lung cancer in men was first classified as causal (7). Subsequent Surgeon General reports have concluded that smoking causes cancer in many other organ sites, including the urinary bladder, esophagus, kidney and renal pelvis, larynx, lung and bronchus, oral cavity and pharynx (OCP), and pancreas (7–16). In 2004, the Surgeon General expanded the sites to include cancers of the stomach and cervix and acute myelogenous leukemia (AML) (17). Thirty percent of cancer deaths, including 87% of lung cancer deaths, are attributable to tobacco use (17,18). The International Agency for Research on Cancer (IARC) also reviewed the evidence on tobacco and cancer in 1986 and in 2002 (19,20). Although the methodology used by IARC differs from that in the Surgeon General reports, their conclusions generally have been similar.

Since the release of the first report of the Surgeon General in 1964, cigarette use and the prevalence of smoking in the United States have decreased. Today, more former smokers exist than current smokers, and each year approximately half of all daily smokers try to quit (21). The decrease in tobacco use since 1964 has been described as one of the 10 greatest achievements in public health in the 20th century (22); however, this rate of progress is unlikely to continue. Trends suggest that the annual rate of cessation among smokers remains fairly low, that the decrease in the smoking initiation rate might have slowed, and that overall adult smoking prevalence might remain at approximately 20%; however, prevalence varies substantially by race and ethnicity (23). Although advances have been made in knowledge of tobacco use and its health

consequences, intervention strategies to reduce tobacco use must continue.

Ongoing surveillance of cancer associated with tobacco use is essential to evaluate the effectiveness of tobacco control programs and policies and identify populations that would benefit from targeted cessation intervention programs or policies. Cancer incidence data are an important resource used in the prevention and control of cancer (24); these data have been used previously at the state level to measure the effectiveness of cigarette tax implementation and smoking restrictions (25). In the analysis described in this report, data were obtained from cancer registries affiliated with CDC's National Program of Cancer Registries (NPCR) and the National Cancer Institute's (NCI's) Surveillance, Epidemiology, and End Results (SEER) program to describe the incidence of tobacco-related cancers in the United States. Results are presented by demographic and tumor characteristics and by state and U.S. census region. In addition, recent trends in cancer incidence are described. Combined data from the NPCR and SEER programs provide the best source of information on population-based cancer incidence for the nation and the only source of information for 41 states (including the District of Columbia [DC]) with cancer surveillance programs that are funded solely by NPCR.

## Methods

Data on new cases of cancer diagnosed during 1999–2004 and collected by cancer registries affiliated with the NPCR or SEER programs were included in analyses. Tobacco-related cancers were defined according to the 2004 report of the Surgeon General on *The Health Consequences of Smoking* (17), in which evidence was determined to be sufficient to infer a causal relationship between tobacco use and the following cancers (with corresponding site and morphology codes according to the *International Classification of Diseases for Oncology*, third edition [ICD-O-3]): lung and bronchus (C34), larynx (C32), OCP (C0-14), esophagus (C15), stomach (C16), pancreas (C25), kidney and renal pelvis (C64–65), urinary bladder (C67), cervix (C53), and AML (M9840, 9861, 9866, 9867, 9871–9874, 9891, 9895–9897, 9910, 9920) (26,27). Because information on tobacco use was not available in the NPCR or SEER databases, cases of cancer included in this report might or might not be in persons who used tobacco; however, the cancer types included in this report are those defined as tobacco related by the Surgeon General (i.e., having a direct causal relationship with tobacco use). CDC analyzed the most recent data available: data reported to NPCR as of January

31, 2007, and to SEER as of November 2006 and made available through a limited-use data file in April 2007.

For demographic, tumor, and trend analyses (Tables 1–11), diagnoses during 1999–2004 from 44 states and DC were included because data from these states and DC for this time period were considered high quality according to the *United States Cancer Statistics* publication criteria (27); these data represent 92.1% of the U.S. population. For state and regional analyses (Figures 1–19), diagnoses from 2004 from 49 states and DC were used. Using a single year of data resulted in a greater number of states with high-quality data (27); these data represent 98.1% of the U.S. population. For the U.S. Census regions, these data represent 100% of the U.S. population for the Northeast, Midwest, and West and 94.1% for the South. U.S. Census regions were defined according to the U.S. Census Bureau (available at <http://www.census.gov/popest/geographic>).

Other than for urinary bladder cancer, only cases of invasive cancer were included. Cases of urinary bladder cancer include in situ tumors that are routinely recoded as invasive for the purpose of cancer incidence reporting because of historical difficulties in distinguishing between the two types (28). Only microscopically confirmed cancer cases were included in tumor analyses (i.e., histology, stage, and grade).

Rates and corresponding 95% confidence intervals (CIs) were calculated for age, race, ethnicity, and sex. Data for American Indian/Alaska Natives (AI/ANs) were cross-checked with Indian Health Service (IHS) records to decrease the number of AI/ANs who were misclassified as nonnative (29). The North American Association of Central Cancer Registries Hispanic Identification Algorithm was applied to Hispanic ethnicity data to reduce misclassification of Hispanics as being of unknown ethnicity. Incidence rates, per 100,000 persons, are age adjusted by 19 age groups to the 2000 U.S. standard population by the direct method (27). Population estimates used as denominators in the rate calculations are from the U.S. Census Bureau and modified by SEER to increase the accuracy of rates (27). The SEER modification is used to reduce the estimated white population and increases the estimated Asian/Pacific Islander (A/PI) population for Hawaii because of concerns that the Native Hawaiian population has been substantially undercounted in previous censuses. The estimates for the total population, black population, and AI/AN populations in Hawaii are not modified. Statistical testing for differences in rates was not performed because of issues with multiple comparisons. CIs were calculated as modified gamma intervals (30) and are presented to allow for informal comparisons among rates. Although examining overlap between CIs to determine significance is conservative (31),

the power for detecting differences in rates with this method is still very high with 6 years of national data. All rate calculations were performed using SEER\*Stat (available at <http://seer.cancer.gov/seerstat>).

Percentages for tumor characteristics (i.e., histology, stage, and grade) were calculated for all cancer types except AML. Histology categories were organized according to ICD-O-3 morphology codes (26). Cystic, mucinous, and serous adenocarcinomas were combined into one adenocarcinoma category. Histology categories for each cancer site were determined by incidence or clinical relevance. Cancer cases were staged as localized, regional, distant, or unknown\* using the 2000 SEER summary staging system, a system routinely used by cancer registries, incorporating information from the American Joint Committee on Cancer staging system (32). Because SEER summary staging guidelines changed substantially beginning with diagnoses made in 2001 (32) and the method used by registries to stage cases changed in 2004, all stage analyses were limited to diagnoses occurring during 2001–2003. For urinary bladder cancer cases, the localized stage includes in situ cases.

Linear trends in the age-adjusted incidence rates were calculated as an estimated annual percentage change (EAPC) during the study period (1999–2004) using the weighted least squares method in SEER\*Stat. P values <0.05 for the two-sided hypothesis test that the EAPC is equal to zero were considered statistically significant.

## Results

### Lung and Bronchial Cancer

A total of 1,095,305 lung and bronchial cancer cases (69.4 per 100,000 persons) were diagnosed in the United States during 1999–2004 (Table 1). Incidence rates were substantially higher among men (89.6) compared with women (54.7). Among persons aged <80 years, rates increased with increasing age and peaked among persons aged 70–79 years (424.4). Among men, blacks had the highest rates (111.0), followed by white men (88.7). A/PI and AI/AN men had similar rates (52.9 and 52.8, respectively). Among women, whites had the highest rates (56.0), followed by blacks (50.3), AI/ANs (35.7), and A/PIs (27.2). Rates were nearly two times higher among non-Hispanics compared with Hispanics (71.8 and 37.4, respectively). Among those with known tumor characteristics, a total of 75.5% of all lung and bronchial cancer cases were

\*Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.



non-small cell carcinomas. Men had greater percentages of squamous cell carcinoma than women (26.0% and 17.3%, respectively), whereas women had greater percentages of adenocarcinomas than men (40.7% and 33.1%, respectively). Almost half (46.5%) of lung and bronchial cancer cases were diagnosed at the distant stage; in addition, almost half were of unknown grade (43.4%), followed by poorly differentiated grade (28.7%). Among men in 2004, lung and bronchial cancer incidence rates were highest in the South region of the United States (97.9) and lowest in the West (66.0) (Figure 1). Among women, rates were similar in the South, Midwest, and Northeast regions (55.3–56.4) and were lowest in the West (48.1) (Figure 2). Arkansas, Delaware, Kentucky, Maine, Oklahoma, and West Virginia had some of the highest rates of lung and bronchial cancer among both men (98.9–133.2) and women (59.8–75.5) (Figures 1 and 2).

### Laryngeal Cancer

A total of 67,618 cases (4.3 per 100,000 persons) of laryngeal cancer were diagnosed in the United States during 1999–2004 (Table 2). Incidence rates were substantially higher among men (7.6) compared with women (1.6). Among persons aged <80 years, rates increased with increasing age and peaked among those aged 70–79 years (19.3). Blacks had the highest rates (6.3 per 100,000 persons), followed by whites (4.1), AI/ANs (2.2), and A/PIs (1.5). Rates were higher among non-Hispanics than Hispanics (4.3 and 3.4, respectively). Among those with known tumor characteristics, almost all (96.5%) laryngeal cancer cases were squamous cell carcinomas. The majority (57.2%) were diagnosed at a localized stage; however, a smaller percentage of localized cases occurred among women (51.5%) than men (58.7%). Women had greater percentages of regional stage laryngeal cancer diagnoses than men (32.4% and 24.3%, respectively), whereas men had slightly greater percentages of distant stage diagnoses than women (9.8% for men and 8.1% for women). Almost half (46.3%) of laryngeal cancer cases were moderately differentiated at diagnosis. Among men in 2004, laryngeal cancer incidence rates were highest in the South (8.4) region of the United States and lowest in the West (4.8) (Figure 3). Among women, rates were similar in the South, Midwest, and Northeast regions (1.6–1.7) and were lowest in the West (1.1) (Figure 4). Alabama, Arkansas, Kentucky, and Louisiana had some of the highest rates of laryngeal cancer cases among both men (8.4–10.7) and women (2.1–2.6) (Figures 3 and 4).

### Oral Cavity and Pharyngeal Cancer

A total of 169,043 cases (10.6 per 100,000 persons) of OCP cancer were diagnosed in the United States during 1999–2004 (Table 3). Incidence rates were substantially higher among men (16.0) compared with women (6.1). Among persons aged <80 years, rates increased with increasing age and leveled among persons aged  $\geq 70$  years (40.3 among those aged 70–79 years and 38.3 among those aged  $\geq 80$  years). Among men, blacks had the highest rates (18.1), followed by white (15.8), A/PI (10.6), and AI/AN (9.5) men. Among women, whites had the highest rates (6.1), followed by black (5.6), A/PI (5.3), and AI/AN women (3.7). Rates were higher among non-Hispanics than Hispanics (11.0 and 7.2, respectively). The highest rates of OCP cancer in men occurred in the oral cavity (7.1) and tonsils (2.4) and in women occurred in the oral cavity (3.3) and salivary glands (0.9). Among those with known tumor characteristics, the majority of OCP cancers were squamous cell carcinomas (83.7%). Most were diagnosed at the localized (36.5%) or regional (46.6%) stage. However, a greater percentage of cases were diagnosed at the localized stage among women (43.7%) than men (33.2%), and a greater percentage of cases diagnosed at the regional stage occurred among men (49.7%) compared with women (39.7%). The majority of OCP cancers were moderately (36.0%) or poorly (23.8%) differentiated at diagnosis. In 2004, rates of OCP cancer were similar by region among men (14.7–16.9) and women (5.7–6.0) (Figures 5 and 6). Alabama, Florida, and Louisiana had some of the highest rates of OCP cancers among both men (17.2–20.2) and women (6.3–9.6) (Figures 5 and 6).

### Esophageal Cancer

A total of 78,561 cases (5.0 per 100,000 persons) of esophageal cancer were diagnosed in the United States during 1999–2004 (Table 4). The incidence rate was higher among men (8.6) compared with women (2.1). Rates were highest among men aged 70–79 years (45.1) and women aged  $\geq 80$  years (14.4). Rates were highest among blacks (6.9), followed by whites (4.8), AI/ANs (3.1), and A/PIs (2.4). Rates were higher among non-Hispanics (5.1) than Hispanics (3.3). Among those with known tumor characteristics, approximately half (56.7%) of all esophageal cancer cases were adenocarcinomas, and approximately one third (36.9%) were squamous cell carcinomas. A similar pattern existed among men (62.8% adenocarcinomas, 31.2% squamous cell carcinomas). However, the pattern differed among women, who had greater percentages of squamous cell carcinomas (55.8%), followed by adenocarcinomas (36.7%). Stage at diagnosis was fairly evenly distributed among localized (23.0%), regional (29.7%), and

distant (28.6%) disease. Men had slightly smaller percentages of localized disease (22.3%) than women (25.4%) and slightly greater percentages of distant disease (30.3%) than women (22.9%). A substantial percentage (41.2%) of esophageal cancer cases were poorly differentiated. In 2004, esophageal cancer rates among men were highest in the Northeast (9.8) and lowest in the West (7.8) (Figure 7). Rates among women were highest in the Northeast and Midwest (2.2) and lowest in the West (1.8) (Figure 8). Connecticut, Delaware, New Hampshire, Rhode Island, and Wisconsin had some of the highest rates of esophageal cancer among men (10.1–13.4) and women (2.4–4.1) (Figures 7 and 8).

## Stomach Cancer

A total of 115,245 cases (7.3 per 100,000) of stomach cancer were diagnosed in the United States during 1999–2004 (Table 5). Incidence rates were higher among men compared with women (10.4 and 4.9, respectively). Rates increased with increasing age and peaked among persons aged  $\geq 80$  years (54.2). A/PIs had the highest rates (14.1), followed by blacks (12.2), AI/ANs (7.1), and whites (6.5). Hispanics had higher rates than non-Hispanics (11.9 and 7.0, respectively). Among those with known tumor characteristics, 90% of stomach cancers were adenocarcinomas (90.3%); gastrointestinal stromal tumors accounted for 3.4%. Approximately 62% of stomach cancers were diagnosed at the regional or distant stage (61.9%), with women having greater percentages of localized stage cancer than men (24.8% and 21.7% respectively). Approximately 50% of stomach cancers were poorly differentiated. In 2004, stomach cancer rates were highest among men in the Northeast (11.7) and lowest in the Midwest and South (9.0) (Figure 9). Rates among women were highest in the Northeast (5.6) and lowest in the Midwest (3.9) (Figure 10). Connecticut, Hawaii, New Jersey, and New York had some of the highest rates of stomach cancer among men (10.2–18.4) and women (5.1–6.7) (Figures 9 and 10).

## Pancreatic Cancer

A total of 176,409 cases (11.2 per 100,000 persons) of pancreatic cancer were diagnosed in the United States during 1999–2004 (Table 6). Incidence rates were higher among men compared with women (12.8 and 9.8, respectively). Rates increased with increasing age and peaked among persons aged  $\geq 80$  years (83.8). Blacks had the highest rates (14.5), followed by whites (10.9), A/PIs (8.6), and AI/ANs (7.2). Non-Hispanics had higher rates than Hispanics (11.2 and 10.3, respectively). Among those with known tumor characteristics, 76.4% of cases of pancreatic cancer were adenocarcinomas,

and 5.7% were mucinous adenocarcinomas. Ductal carcinomas accounted for 6.1% of pancreatic cancer diagnoses. Approximately half (51.6%) of pancreatic cancer cases were diagnosed at the distant stage; 8.1% of pancreatic cancers were diagnosed at the localized stage. The majority (53.8%) of pancreatic cancer cases were of unknown grade at diagnosis. Among men in 2004, pancreatic cancer rates were highest in the Northeast (13.8) and lowest in the West (11.7) (Figure 11). Rates among women were highest in the Northeast (10.9) and lowest in the Midwest (9.2) (Figure 12). Connecticut, DC, Louisiana, New Jersey, and New York had some of the highest rates of pancreatic cancer among men (13.7–14.8) and women (10.9–12.3) (Figures 11 and 12).

## Kidney and Renal Pelvis Cancer

A total of 210,331 cases (13.3 per 100,000 persons) of kidney and renal pelvis cancers were diagnosed in the United States during 1999–2004 (Table 7). Incidence rates were almost twice as high among men (18.1) compared with women (9.4). In persons aged  $< 80$  years, rates increased with increasing age and peaked among men and women aged 70–79 years (83.9 and 42.7, respectively). Blacks had the highest rates (13.6), followed by whites (13.4), AI/ANs (12.4), and A/PIs (6.0). Rates were similar among non-Hispanics (13.3) and Hispanics (13.1). Among those with known tumor characteristics, the majority (87.1%) of cases of kidney cancer were adenocarcinomas, with either renal cell carcinoma (53.7% of the total cases for which histologic characteristics were known) or clear cell adenocarcinoma (20.8% of the total cases for which histologic characteristics were known) as the major adenocarcinoma subtypes. At diagnosis, 63.2% of cases of kidney cancer were at a localized stage, and 31.4% of cases were moderately differentiated. Among men in 2004, kidney cancer incidence rates were highest in the Northeast, South, and Midwest regions of the United States (20.4, 19.7, and 19.3, respectively) and lowest among men in the West (17.0) (Figure 13). Similarly, among women, rates were highest in the Midwest, Northeast, and South regions (10.7, 10.3, and 10.3, respectively) and lowest in the West (8.5) (Figure 14). Illinois, Indiana, Louisiana, Rhode Island, and Texas had some of the highest rates of kidney cancer among men (20.2–23.5) and women (10.8–14.0) (Figures 13 and 14).

## Urinary Bladder Cancer

A total of 342,515 urinary bladder cancer cases (21.7 per 100,000 persons) were diagnosed in the United States during 1999–2004 (Table 8). Incidence rates were approximately four times higher among men (38.2) compared with women (9.7).

Rates increased with increasing age and peaked among persons aged  $\geq 80$  years (321.7 and 74.5, respectively). Whites had the highest rate (22.9), followed by blacks (11.4), A/PIs, (8.8), and AI/ANs (7.5). Rates were higher among non-Hispanics (22.4) than Hispanics (12.3). Among those with known tumor characteristics, the majority of cases of urinary bladder cancer were transitional cell carcinomas (94.0%). At diagnosis, 31.3% of urinary bladder cancers were moderately differentiated and nearly all (99.5%) were diagnosed at a localized stage. Among men in 2004, urinary bladder cancer incidence rates were highest in the Northeast region of the United States (44.7) and lowest in the South (34.1) (Figure 15). Among women, bladder cancer incidence rates were highest in the Northeast (11.8) and lowest in the South and West (8.8) (Figure 16). Connecticut, Delaware, Maine, Massachusetts, Minnesota, New Hampshire, New Jersey, New York, Rhode Island, and Vermont had some of the highest rates of bladder cancer among men (41.6–54.6) and women (10.9–13.9) (Figures 15 and 16).

## Cervical Cancer

A total of 72,878 cervical cancer cases (8.9 per 100,000 women) were diagnosed among women in the United States during 1999–2004 (Table 9). Women aged 40–49 years had the highest rates of cervical cancer (15.6). Rates were highest among blacks (12.5), followed by whites (8.4), A/PIs (8.2), and AI/ANs (6.8). Rates were higher among Hispanics (14.0) compared with non-Hispanics (8.4). Among those with known tumor characteristics, the majority of cervical cancer cases were squamous cell carcinomas (70.8%); adenocarcinomas accounted for 22.7%. Approximately half (50.7%) of cervical cancer cases were diagnosed at the localized stage, and approximately one third (32.7%) were at the regional stage at diagnosis. Most cervical cancers were of unknown grade (32.5%), poorly differentiated (28.5%), or moderately differentiated (28.3%). In 2004, cervical cancer rates were highest in the South (8.6) and lowest in the Midwest and West (7.4) (Figure 17). Arkansas, DC, Florida, Kentucky, Louisiana, Maine, Mississippi, New Jersey, New Mexico, Rhode Island, Texas, West Virginia, and Wyoming had the highest rates of cervical cancer (8.8–13.2) (Figure 17).

## Acute Myelogenous Leukemia

A total of 62,708 AML cases (4.0 per 100,000 persons) were diagnosed in the United States during 1999–2004 (Table 10). Incidence rates were higher among men compared with women (4.9 and 3.3, respectively). Rates increased with increasing age and peaked among persons aged  $\geq 80$  years

(23.0). Whites had the highest rates (4.1), followed by blacks (3.2), A/PIs (3.1), and AI/ANs (2.1). Non-Hispanics had higher rates than Hispanics (4.0 and 3.4, respectively). Among men in 2004, AML incidence rates were highest in the Northeast (5.0) and lowest in the West (4.3) (Figure 18). Rates among women were highest in the Northeast and Midwest (3.4) and lowest in the West (2.9) (Figure 19). Illinois, Maine, and Rhode Island had some of the highest rates of AML among men (5.2–9.0) and women (3.6–5.0) (Figures 18 and 19).

## Estimated Annual Percentage Change in Incidence Rates of Tobacco-Related Cancers

During 1999–2004, significant decreases in cancers of the lung and bronchus (0.91% per year), larynx (2.75%), OCP (0.58%), stomach (1.62%), and urinary bladder (0.39%) occurred among men and women combined (Table 11). A significant decrease also occurred in cervical cancer among women (4.10%). Although lung and bronchial cancer rates decreased overall, rates remained stable among women ( $p = 0.53$ ). The decrease in OCP rates was greater among women (1.30%,  $p = 0.01$ ) than men (0.45%,  $p = 0.06$ ). A significant increase in kidney cancer (3.14% per year) occurred among men and women combined. Significant changes in esophageal and pancreatic cancer and AML did not occur.

## Discussion

### Interpretation of Tobacco-Related Cancer Incidence

Approximately 2.4 million cases of tobacco-related cancer were diagnosed in the United States during 1999–2004, with lung and bronchial cancer accounting for almost half of these diagnoses. The incidence of tobacco-related cancers was higher among men compared with women. Black and non-Hispanic populations had consistently higher incidence rates than other racial and ethnic populations, with a few exceptions. The majority of tobacco-related cancers occurred among persons aged  $\geq 70$  years. The high rates among men, blacks, non-Hispanics, and older adults reflect overall demographic patterns of cancer incidence in the United States (27) and also reflect patterns of tobacco use. In 2006, an estimated 20.8% of all adults in the United States (45.3 million persons) smoked cigarettes, with smoking being more common among men (23.9%) compared with women (18.0%) (23). The prevalence of cigarette smoking varies among racial and ethnic minority groups; the highest prevalence is among AI/ANs



(32.4%), followed by blacks (23.0%), whites (21.9%), Hispanics (15.2%), and A/PIs (10.4%) (23). Although AI/ANs did not have the highest tobacco-related cancer incidence rates overall, incidence rates for this population are known to be substantially underestimated in registry data because of misclassification of race in medical records (29). The relatively lower cancer incidence rates among AI/ANs in this report might be a reflection of this misclassification. Blacks had the highest tobacco-related cancer incidence rates in this report and have the second-highest smoking prevalence among racial and ethnic populations. Some reports suggest that in addition to high smoking rates, blacks might have increased susceptibility to the carcinogens in tobacco smoke or might have increased exposure to carcinogens through increased depth and frequency of inhalation (33).

The incidence rates in this report generally are higher than those reported using SEER data alone from 2000–2004 (which cover 26% of the U.S. population) (34), with the exception of stomach cancer. The higher rate of stomach cancer reflected by SEER data might be a result of higher proportions of A/PIs represented in the SEER program compared with in the United States, which might result in higher incidence rates for cancers that affect A/PIs (35). The higher incidence rates for cancers other than stomach cancer in the combined NPCR and SEER data set compared with SEER data alone are likely a result of the inclusion of data from additional states in the combined data set, especially states with a higher prevalence of tobacco use. Substantial variation in smoking prevalence exists by state among adults in the United States. The states with the highest prevalence of current smokers are located in the South: Kentucky (28.6%), West Virginia (25.7%), Oklahoma (25.1%), and Mississippi (25.1%) (36). Lung, laryngeal, and cervical cancer incidence rates were highest in the South; Kentucky had the highest rates of lung and laryngeal cancers among both men and women. States with the lowest smoking rates were in the West: Utah (10.4%), California, (18.5%), and Montana (18.5%) (36). Cancer incidence rates were consistently lowest in the West for all the cancers in this report, with the exception of stomach cancer.

Cancers of the lung and bronchus, larynx, and OCP have the greatest average relative risks associated with tobacco use (37) (Table 12). Lung cancer is the second most commonly diagnosed cancer in men (after prostate cancer) and women (after breast cancer) and is the leading cause of cancer death among both men and women in the United States (27). The average tobacco-related lung cancer relative risk is 15.0–30.0 (37). Tobacco use causes all histologic types of lung cancer; however, differences in smoking patterns and exposures to other lung carcinogens result in variations in incidence by his-

tologic type (38). Consistent with previous studies, the results of this study demonstrate that squamous cell carcinoma rates are higher among men, whereas adenocarcinoma rates are higher among women (38). Adenocarcinoma rates increased in the 1980s and 1990s (39), and adenocarcinoma is now the most common type of lung cancer among smokers (17,20). Certain data suggest that changes in the cigarette composition, carcinogen levels in cigarette smoke, and smoking behaviors are responsible for the changing histologic characteristics of lung cancer among smokers (40); however, the direct relationship of these factors to these changes has not been established (17,20). The introduction of filters and the modification of cigarette design and composition to reduce the machine-tested level of tar and nicotine has resulted in smokers inhaling more frequently and deeply and other compensatory smoking behaviors to sustain nicotine intake (40). As a result, cigarette smoke comes into direct contact with more of the lung periphery (i.e., the site where adenocarcinoma develops) than with the central lung and bronchus (i.e., the site where squamous cell carcinoma develops) (17,20,40). In addition, changes in cigarette design, composition, and tobacco blends have been associated with changes in the level of carcinogens consistent with the changes in the incidence of histologic types (i.e., reductions in polynuclear aromatic hydrocarbons and increases in tobacco-specific nitrosamine levels) (17,20,40). The significant decrease in lung cancer rates that occurred among men but not among women in this study is consistent with other studies (38) and is related to historical patterns of smoking prevalence. Smoking prevalence continued to increase among women as it was decreasing among men, leading to diverging patterns of lung cancer incidence between men and women (41).

Laryngeal cancer is relatively rare in the United States (27). The tobacco-related relative risk for laryngeal cancer is 10.0 (37). A recent case-control study confirms that tobacco use is the most substantial risk factor for laryngeal cancer (42). In addition to tobacco use, alcohol use has an important etiologic role in the formation of laryngeal cancer, and these two factors have a synergistic effect on laryngeal cancer risk (42). Diets low in vegetable consumption also might increase the risk for laryngeal cancer among women smokers (42). In this study, the high incidence rates of both lung and laryngeal cancer in the South are consistent with smoking patterns and reflect the strong association of these cancers with tobacco use.

OCP cancer is the eighth most common cancer in the United States among men but is less common among women (27). This type of cancer includes tumors with origins in several anatomic organs of the head and neck. Strong evidence associates tobacco as the carcinogenic factor in squamous cell can-

cer of the head and neck (43), which the findings from this study indicate is the predominant histologic type of OCP cancers in the United States. Smokeless tobacco use also is strongly associated with OCP cancer (44), and the average relative risk for tobacco-related OCP cancer is 4.0–5.0 (37). Alcohol is a strong risk factor for OCP cancer as well, and studies have shown that the use of both tobacco and alcohol has a synergistic effect on the development of OCP cancer, together accounting for 80%–90% of all cases of OCP cancers (43,45). Among women, OCP cancers were highest among whites, a finding that might partly be related to the higher prevalence of smokeless tobacco use among white men and women (44).

Cancers of the pancreas and urinary bladder have similar relative risks associated with tobacco use (pancreas, 2.0–4.0; urinary bladder, 3.0) (37). Pancreatic cancer is among the top 10 cancers diagnosed and is the fourth leading cause of cancer death among men and women in the United States (27). Although little is known about the etiology of pancreatic cancer, smoking is the strongest environmental risk factor that has been identified for this cancer (46). Studies also have linked smokeless tobacco use to pancreatic cancer, with N-nitrosamines in these products being the plausible carcinogenic agents (47,48). Nearly all studies have shown that persons who use tobacco products have at least a twofold increased risk of developing pancreatic cancer compared with nonusers (46,47). Obesity, inflammation from pancreatitis, and several genetic syndromes also are associated with increased risk for pancreatic cancer (46). The incidence of pancreatic cancer found in this study remained stable during the study period. This finding is in contrast to findings from a recent study covering 10% of the U.S. population, which found significant decreases in pancreatic cancer during 1973–2002 (49). The difference in trends between these two studies likely is a result of substantial differences in population coverage and differences in the time period studied. Certain studies have suggested that improvements in diagnostic modalities during the last 20 years have greatly improved the accuracy of pancreatic cancer diagnoses (46). These improvements could be related to the stability in incidence rates observed in this study.

Urinary bladder cancer is the fourth most commonly diagnosed cancer among men in the United States (27). Among women, this cancer is far less common, ranking tenth among white women and lower among women of other races (27). The decrease in bladder cancer incidence rates reported in this study among men and women is consistent with findings from other studies. Longer-term trend analyses using SEER data alone suggest that this decrease began recently for men but has been occurring for several decades among women (29). Among persons who smoke, the risk of developing bladder

cancer increases with lifetime duration of smoking and number of cigarettes smoked per day and decreases among former smokers (50,51). Results of a case-control study in Europe suggest that after cessation of smoking, the risk of bladder cancer decreases by approximately 40% within 1–4 years (50).

AML and esophageal, kidney, stomach, and cervical cancers have similar relative risks associated with tobacco use (1.5–2.5) (37). Esophageal cancer is not as commonly diagnosed in the United States as certain other cancers discussed in this report; however, esophageal cancer is one of the top 10 leading causes of cancer death among most racial and ethnic populations (27). Smoking is more strongly associated with squamous cell carcinoma of the esophagus than adenocarcinoma of the esophagus (52). Several studies have indicated that smokers have a twofold to threefold increase in risk for developing esophageal adenocarcinoma; however, esophageal adenocarcinoma risk remains elevated after cessation of tobacco use, and this risk might persist for 30 years (53). The relatively greater percentages of adenocarcinoma among men in this study might be related to this persistently elevated risk, and decreases in the incidence of this histologic type might take longer to be observed. The lack of a decrease in esophageal cancer incidence might also be related to this persistently elevated risk but could be related to trends in alcohol use and obesity, which are also established risk factors (52).

Kidney cancer is a frequently diagnosed cancer among both men and women in the United States (27). Risk factors for kidney cancer are not well understood. For both men and women, kidney cancer risk was found to increase with duration of lifetime smoking and number of cigarettes smoked per day and to decrease among former smokers (54). In addition to smoking, obesity and hypertension are emerging as risk factors for kidney cancer (55). For both men and women, kidney cancer rates increased during the study period. These findings are similar to those from a study of long-term SEER data, which found that this increase has been evident for both men and women during the past several decades (29) and might be a result of the prevalence of obesity (56). Certain studies also suggest that the increase in kidney cancer rates might be a result of increased detection of kidney cancer through the increased use of ultrasound and computed tomography for non-cancer-related conditions (57).

Stomach cancer is common among certain racial and ethnic populations in the United States (27). Tobacco use is related to both cardia and noncardia stomach cancer; the association with noncardia adenocarcinoma is stronger (58). Risk is related to number of cigarettes smoked per day and lifetime duration of smoking, and the risk decreases by approximately 30% among former smokers (59). In addition

to tobacco use, the major risk factors for stomach cancer include a diet of salted foods and smoked meat and chronic infection with *Helicobacter pylori* (60), which was determined to be a carcinogen by IARC in 1994 (61). *H. pylori* plays a much larger role in stomach cancer etiology in areas of the world where the prevalence of infection is higher, especially in Asian countries, which have 70% of cases of stomach cancer worldwide (60). Several studies have reported that racial and ethnic populations other than whites have higher prevalences of *H. pylori* infection (62,63). These findings are consistent with the results of this study, which found higher stomach cancer incidence rates in these populations. Persons who smoke are more likely to develop persistent infections with *H. pylori* and less likely to respond to antibiotic treatment for the infection (64). The finding in this study that stomach cancer incidence has been decreasing in recent years is consistent with findings of other studies that have demonstrated decreases during the last several decades (29) and might be a result of increases in consumption of fresh fruits and vegetables, decreases in the consumption of salt-preserved food, and decreases in the prevalence of *H. pylori* infection.

Although the overall incidence of cervical cancer is low in the United States, black and Hispanic women continue to have a higher incidence of this cancer than white women (27). Smoking consistently has been associated with higher risks of cervical cancer, and this risk increases with the lifetime duration of smoking and number of cigarettes smoked per day (65). Carcinogenic chemicals consistent with tobacco use have been found in cervical mucous (66), as have changes in DNA (i.e., formation of adducts) (67). Although tobacco use is related to cervical cancer, the primary risk factor is human papillomavirus (HPV) infection, which is a sexually transmitted disease. HPV infection likely accounts for the lower peak age (40–49 years) of incidence of cervical cancer in this report, as well as the high rate among Hispanic women (68). Smoking and HPV might also act synergistically in the occurrence of cervical cancer. Recent studies show consistently that smoking is associated with an increased risk for developing cervical cancer among HPV-positive women (69). The increased risk is moderate (odds ratio = 2.17; CI = 1.46–3.22) and is not likely to be a result of confounding by varying sexual behaviors (59), because all women were HPV-positive in these analyses. The decrease in cervical cancer rates is likely a result of continued screening, which identifies premalignant lesions that are removed before a malignancy occurs (29).

AML is a relatively rare cancer in the United States (27). Current cigarette smoking is an established risk factor for AML; in populations with a high prevalence of smoking, 20% of AML cancers are attributable to tobacco use among current

smokers (70). Smoking is thought to increase risk through exposure to benzene, an environmental agent consistently associated with AML, and other carcinogens found in tobacco. AML incidence was highest among white men and women, and Vermont had the highest incidence rate among men in 2004, findings that are inconsistent with smoking patterns. This lends support to the multiple factors involved in AML etiology, which is related to race and ethnicity, environmental exposures, and genetic risk factors that have not yet been determined. Several recent reports have implicated obesity as an emerging risk factor for AML (71).

The detailed cancer incidence data in this report provide a baseline measurement that can be used in future monitoring of cancer incidence trends. As more geographically complete incidence data become available for all populations in the United States, researchers might be able to further describe patterns of cancer incidence that are specifically related to tobacco use, similar to studies of mortality disparities (72). This will ensure that any reductions in the incidence of tobacco-related cancers are maintained and disparities in incidence are identified.

## Limitations

The findings in this report are subject to at least three limitations. First, information about smoking status and other risk factors for cancer (e.g., obesity or HPV) is not available in cancer registry data. Therefore, although the overall incidence of tobacco-related cancers in the United States is presented, the association between the development of these cancers and tobacco and other etiologic could not be determined. Second, data for AI/ANs have been shown to be considerably underreported in cancer registries (73). Linkage with external sources of information such as IHS administration records improved the quality of AI/AN data in this study (29); however, because IHS only serves federally recognized tribes, these data might not fully represent all AI/ANs, especially those in state-recognized tribes. Finally, although this study covered >90% of the U.S. population and is the most inclusive study of the U.S. population, high-quality incidence data were not available from Maryland, Mississippi, North Dakota, South Dakota, Tennessee, and Virginia for the study period.

## Public Health Action

In 2007, the Institute of Medicine (IOM) presented a blueprint for action to “reduce smoking so substantially that it is no longer a public health problem for our nation” (74). The two-pronged strategy for achieving this goal included not only strengthening and fully implementing proven tobacco con-

trol measures but also changing the regulatory landscape to permit policy innovations. The primary IOM recommendation is that each state should fund a comprehensive tobacco control program at the level recommended by CDC (74,75).

CDC recommends that states establish and sustain tobacco control programs that contain the following components: state and community interventions, health communication interventions, cessation interventions, surveillance and evaluation, and administration and management (75). *Best Practices for Comprehensive Tobacco Control Programs — 2007* is an evidence-based guide designed to help states plan and establish effective tobacco control programs to prevent and reduce tobacco use (75). Each state is provided a recommendation for the annual investment necessary to prevent initiation of tobacco use, promote cessation among those already using tobacco, eliminate exposure to secondhand smoke, and eliminate tobacco-use-related disparities, such as differences in patterns of use, cessation, morbidity, exposure, and access to resources (75). Additional support for tobacco control comes from CDC's National Comprehensive Cancer Control Program, which provides financial support and advice to aid states in developing and implementing cancer control plans. Comprehensive cancer control is based on the premise that effective cancer control planning and program implementation at the local, state, and national levels address a continuum of services, including primary prevention and early detection, quality cancer treatment, and addressing the needs of cancer survivors (76). A recent assessment concluded that nearly one half of 39 published plans addressed tobacco control; however, plans varied widely and can be improved (76).

States that have made tobacco control a priority have benefited from this commitment. For example, California, which has the longest-running comprehensive tobacco control program in the United States, reduced adult smoking prevalence from 22.7% in 1998 to 13.3% in 2006 (77). The incidence of lung cancer has decreased nearly four times more quickly in California than in the rest of the United States, which likely is partly a result of program-related reductions in smoking (78,79), and during 1987–1997, an estimated 11,000 cases of lung cancer were prevented (80). Additional states such as Florida (81), Maine, New York, and Washington (82–84) also have been successful in reducing smoking among adults and youths. Cancer incidence in these and other states should continue to be monitored at the local, state, and national levels to measure the impact of these public health successes in reducing the effects of tobacco use.

Ongoing cancer incidence reporting is essential to help identify types of cancers, in addition to those reported in this study, that might also be causally related to tobacco use. In 2004,

the Surgeon General concluded that evidence was suggestive but not sufficient to infer a causal relationship between smoking and colorectal adenomatous polyps and colorectal cancer (17). Several more recently published studies have provided additional data implying a potential causal relationship (85–87); however, the relationship might be stronger for rectal than colon cancer (86). Current and former smoking should be considered a potential risk factor for colorectal cancer in clinical and public health settings, and future research should focus on evaluating the association between smoking and colorectal cancer risk.

The Surgeon General also concluded that the evidence is suggestive but not sufficient to infer a causal relationship between smoking and liver cancer (17); however, IARC review concluded that the data were sufficient to infer a causal relationship (20). Although substantial epidemiologic evidence suggests a relationship between smoking and liver cancer, the 2004 Surgeon General report review determined that important questions remain regarding the impact of hepatitis infection and alcohol use on the relationship between smoking and liver cancer (17). The strength of an association between cigarette smoking and liver cancer varies according to hepatitis B virus (HBV) infection status, with stronger associations among persons who are not infected with HBV. Additional research is needed to establish the possible association between smoking and liver cancer, with further consideration of the history of hepatitis infection and other confounding factors such as alcohol use.

Breast cancer risk related to tobacco smoke exposure also has been recognized (17,89,90). However, the 2006 Surgeon General report *The Health Consequences of Involuntary Exposure to Tobacco Smoke* concludes that the evidence is suggestive but not sufficient to infer a causal relationship between secondhand smoke and breast cancer (88). The 2004 IARC publication *Tobacco Smoke and Involuntary Smoking* concluded that active smoking is not associated with an increased risk for breast cancer in studies that compare active smokers with persons who have never smoked (20). However, the lack of evidence for an increase in breast cancer risk among active, female smokers does not exclude the possibility that certain subgroups of female smokers might be at increased risk because of genetic or other factors.

Additional research and evaluation of data are needed to help determine whether a causal relationship exists between smoking and certain cancers such as colorectal, liver, and breast cancer. If the evidence indicates that these cancers, and perhaps other types, are associated with smoking, the incidence of cancer attributed to smoking in the United States might rise substantially. Ongoing surveillance and reporting are



essential to monitor cancer incidence trends, identify populations at greatest risk for developing tobacco-related cancers, and evaluate the effectiveness of targeted tobacco control programs and policies.

## References

1. CDC. Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. *MMWR* 2005;54:625–8.
2. National Toxicology Program. 11th report on carcinogens, 2005. Research Triangle Park, NC: US Department of Health and Human Services, National Institute of Environmental Health Sciences; 2000.
3. Giovino GA. The tobacco epidemic in the United States. *Am J Prev Med* 2007;33 (Suppl 3):S318–326.
4. McGinnis JM, Foege WH. Actual causes of death in the United States. *JAMA* 1993;270:2207–12.
5. Doll R, HILL AB. The mortality of doctors in relation to their smoking habits: a preliminary report. *Br Med J* 1954;1:1529–33.
6. Doll R, HILL AB. Lung cancer and other causes of death in relation to smoking: a second report on the mortality of British doctors. *Br Med J* 1956;2:1071–81.
7. US Department of Health, Education, and Welfare. Smoking and health. Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DC: US Department of Health, Education, and Welfare; Public Health Service; 1964.
8. US Department of Health, Education, and Welfare. The health consequences of smoking: a public health service review, 1967. Washington, DC: US Department of Health, Education, and Welfare; Public Health Service; 1967.
9. US Department of Health, Education, and Welfare. The health consequences of smoking: 1968. supplement to the 1967 public health service review. Washington, DC: US Department of Health, Education, and Welfare; Public Health Service; 1968.
10. US Department of Health, Education, and Welfare. The health consequences of smoking: a report of the Surgeon General: 1971. Washington, DC: US Department of Health, Education, and Welfare; Public Health Service; Mental Health Administration; 1971.
11. US Department of Health, Education, and Welfare. The health consequences of smoking: a report of the Surgeon General; 1972. Washington, DC: US Department of Health, Education, and Welfare; Public Health Service; Health Services and Mental Health Administration; 1972.
12. US Department of Health, Education, and Welfare. The health consequences of smoking: a report of the Surgeon General; 1974. Washington, DC: US Department of Health, Education, and Welfare; Public Health Service; CDC; 1974.
13. US Department of Health, Education, and Welfare. Smoking and health: a report of the Surgeon General. Washington, DC: US Department of Health, Education, and Welfare; Public Health Service; 1979.
14. US Department of Health and Human Services. The health consequences of smoking for women: a report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Public Health Service; 1980.
15. US Department of Health and Human Services. The health consequences of smoking: cancer: a report of the Surgeon General. Washington, DC: US Department of Health and Human Services, Public Health Service; 1982.
16. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC; 1990.
17. US Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC; 2004.
18. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. New York, NY: Oxford Press, 1981.
19. International Agency for Research on Cancer. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans: tobacco smoking, Volume 38. Lyon, France: International Agency for Research on Cancer; 1986.
20. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans: tobacco smoke and involuntary smoking. Vol. 83. Lyon, France: International Agency for Research on Cancer; 2004.
21. CDC. Cigarette smoking among adults—United States, 2001. *MMWR* 2003;52:953–6.
22. CDC. Achievements in public health, 1900–1999: tobacco use—United States, 1900–1999. *MMWR* 1999;48:986–93.
23. CDC. Cigarette smoking among adults—United States, 2006. *MMWR* 2007;56:1157–61.
24. Glaser SL, Clarke CA, Gomez SL, et al. Cancer surveillance research: a vital subdiscipline of cancer epidemiology. *Cancer Causes Control* 2005;16:1009–19.
25. Black BL, Cowens-Alvarado R, Gershman S, Weir HK. Using data to motivate action: the need for high quality, an effective presentation, and an action context for decision-making. *Cancer Causes Control* 2005;16(Suppl 1):15–25.
26. Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
27. US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007.
28. Lynch CF, Platz CE, Jones MP, Gazzaniga JM. Cancer registry problems in classifying invasive bladder cancer. *J Natl Cancer Inst* 1991; 83:429–33.
29. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. *Cancer*. 2007;110:2119–52.
30. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. *Stat Methods Med Res* 2006;15:547–69.
31. Schenker N, Gentleman JF. On judging the significance of differences by examining overlap between confidence intervals. *Am Stat* 2001; 55:182–6.
32. National Cancer Institute. SEER summary staging manual 2000. Bethesda, MD: National Cancer Institute; 2000.
33. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. *N Engl J Med* 2006;354:333–42.
34. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975–2004. Bethesda, MD: National Cancer Institute; 2004. Available at [http://seer.cancer.gov/csr/1975\\_2004/index.html](http://seer.cancer.gov/csr/1975_2004/index.html)

35. Wingo PA, Jamison PM, Hiatt RA, et al. Building the infrastructure for nationwide cancer surveillance and control—a comparison between the National Program of Cancer Registries (NPCR) and the Surveillance, Epidemiology, and End Results (SEER) Program (United States). *Cancer Causes Control* 2003;14:175–93.
36. CDC. State-specific prevalence of cigarette smoking among adults and quitting among persons aged 18–35 years—United States, 2006. *MMWR* 2007;56:993–6.
37. Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological evidence. *J Natl Cancer Inst* 2004;96:99–106.
38. Devesa SS, Bray F, Vizcaino AP, Parkin DM. International lung cancer trends histologic type: male:female differences diminishing and adenocarcinoma rates rising. *Int J Cancer* 2005;117:294–9.
39. Thun MJ, Lally CA, Flannery JT, et al. Cigarette smoking and changes in the histopathology of lung cancer. *J Natl Cancer Inst* 1997;89:1580–6.
40. National Cancer Institute. Risks associated with smoking cigarettes with low machine-measured yields of tar and nicotine. Smoking and tobacco monograph no. 13. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2001.
41. Baldini EH, Strauss GM. Women and lung cancer: waiting to exhale. *Chest* 1997;112(Suppl 4):S229–34.
42. Gallus S, Bosetti C, Franceschi S, et al. Laryngeal cancer in women: tobacco, alcohol, nutritional, and hormonal factors. *Cancer Epidemiol Biomarkers Prev* 2003;12:514–7.
43. Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? *Cancer* 2007;110:1429–35.
44. Nelson DE, Mowery P, Tomar S, et al. Trends in smokeless tobacco use among adults and adolescents in the United States. *Am J Public Health* 2006;96:897–905.
45. Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. *J Dent Res* 2007;86:104–14.
46. Lowenfels AB, Maisonneuve P. Epidemiology and prevention of pancreatic cancer. *Jpn J Clin Oncol* 2004;34:238–44.
47. Boffetta P, Castaing M, Brennan P. A geographic correlation study of the incidence of pancreatic and other cancers in whites. *Eur J Epidemiol* 2006;21:39–46.
48. Alguacil J, Silverman DT. Smokeless and other noncigarette tobacco use and pancreatic cancer: a case-control study based on direct interviews. *Cancer Epidemiol Biomarkers Prev* 2004;13:55–8.
49. Zhang J, Dhakal I, Yan H, Phillips M, Kesteloot H. Trends in pancreatic cancer incidence in nine SEER cancer registries, 1973–2002. *Ann Oncol* 2007;18:1268–79.
50. Brennan P, Bogillot O, Cordier S, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. *Int J Cancer* 2000;86:289–94.
51. Brennan P, Bogillot O, Greiser E, et al. The contribution of cigarette smoking to bladder cancer in women (pooled European data). *Cancer Causes Control* 2001;12:411–7.
52. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. *Cancer* 1998;83:2049–53.
53. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. *J Natl Cancer Inst* 1997;89:1277–84.
54. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. *N Engl J Med* 2000;343:1305–11.
55. Flaherty KT, Fuchs CS, Colditz GA, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). *Cancer Causes Control* 2005;16:1099–106.
56. Liu S, Semenciw R, Morrison H, Schanzer D, Mao Y. Kidney cancer in Canada: the rapidly increasing incidence of adenocarcinoma in adults and seniors. *Can J Public Health*;88:99–104.
57. Stafford HS, Saltzstein SL, Shimasaki S, et al. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. *J Urol* 2008;179:1704–8.
58. Engel LS, Chow WH, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. *J Natl Cancer Inst* 2003;95:1404–13.
59. Kuper H, Boffetta P, Adami HO. Tobacco use and cancer causation: association by tumour type. *J Intern Med* 2002;252:206–24.
60. Correa P. *Helicobacter pylori* infection and gastric cancer. *Cancer Epidemiol Biomarkers Prev* 2003;12:238s–41s.
61. International Agency for Research on Cancer. Schistosomes, liver flukes and *Helicobacter pylori*. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monogr Eval Carcinog Risks Hum 1994;61:1–241.
62. Cardenas VM, Mulla ZD, Ortiz M, Graham DY. Iron deficiency and *Helicobacter pylori* infection in the United States. *Am J Epidemiol* 2006;163:127–34.
63. McMahon BJ, Bruce MG, Hennessy TW, et al. Reinfection after successful eradication of *Helicobacter pylori*: a 2-year prospective study in Alaska Natives. *Aliment Pharmacol Ther* 2006;23:1215–23.
64. Cardenas VM, Graham DY. Smoking and *Helicobacter pylori* infection in a sample of U.S. adults. *Epidemiology* 2005;16:586–90.
65. CDC. Women and smoking: a report of the Surgeon General. Executive summary. *MMWR* 2002;51(No. RR-12):i–iv.
66. Holly EA, Petrakis NL, Friend NF, et al. Mutagenic mucus in the cervix of smokers. *J Natl Cancer Inst* 1986;76:983–6.
67. Simons AM, Phillips DH, Coleman DV. DNA adduct assay in cervical epithelium. *Diagn Cytopathol* 1994;10:284–8.
68. Saraiya M, Ahmed F, Krishnan S, et al. Cervical cancer incidence in a prevaccine era in the United States, 1998–2002. *Obstet Gynecol* 2007;109:360–70.
69. Plummer M, Herrero R, Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. *Cancer Causes Control* 2003;14:805–14.
70. Petridou E, Trichopoulos D. Leukemias. In: Adami H, Hunter D, Trichopoulos D, editors. *Textbook of cancer epidemiology*. New York, NY: Oxford University Press; 2002.
71. Fernberg P, Odenbro A, Bellocco R, et al. Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: a nationwide cohort study in Sweden. *Cancer Res*. 2007;67:5983–6.
72. Ezzati M, Friedman AB, Kulkarni SC, Murray CJ. The reversal of fortunes: trends in county mortality and cross-county mortality disparities in the United States. *PLoS Med* 2008;55:e66.
73. Clegg LX, Reichman ME, Hankey BF, et al. Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. *Cancer Causes Control* 2007;18:177–87.
74. Institute of Medicine. *Ending the tobacco problem: a blueprint for the nation*. Washington, DC: The National Academies Press; 2007.

75. CDC. Best practices for comprehensive tobacco control programs—2007. Atlanta, GA: US Department of Health and Human Services, CDC; 2007.
76. Kilfoy BA, Hudmon KS, Mande JR. Tobacco control in state comprehensive cancer control plans: opportunities for decreasing tobacco-related disease. *Prev Chronic Dis* 2007;4:A61.
77. California Department of Health Services. New data show 91 percent of California women don't smoke. News Release No. 07-37. May 22, 2007. Available at <http://www.applications.dhs.ca.gov/pressreleases/store/pressreleases/07-37%20dhs%20smoking%20rates-with%20charts.html>
78. CDC. Declines in lung cancer rates—California, 1988–1997. *MMWR* 2000;49:1066–9.
79. California Department of Health Services. California tobacco control update 2006: the social norm change approach. Sacramento, CA: California Department of Health Services; 2006.
80. Barnoya J, Glantz S. Association of the California tobacco control program with declines in lung cancer incidence. *Cancer Causes Control* 2004;15:689–95.
81. Bauer UE, Johnson TM, Hopkins RS, Brooks RG. Changes in youth cigarette use and intentions following implementation of a tobacco control program: findings from the Florida Youth Tobacco Survey, 1998–2000. *JAMA* 2000;284:723–8.
82. CDC. Youth Risk Behavior Surveillance System. Youth online: comprehensive results. Available at <http://apps.nccd.cdc.gov/yrbss>.
83. RTI International. Fourth annual independent evaluation report of New York's tobacco control program. Albany, NY: New York State Department of Health; 2007.
84. Washington State Department of Health. Tobacco prevention and control program progress report, March 2007: producing results for a healthier Washington. Olympia, WA: Washington State Department of Health; 2007.
85. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and adenomatous polyps: a meta-analysis. *Gastroenterology* 2008;134:388–95.
86. Paskett ED, Reeves KW, Rohan TE, et al. Association between cigarette smoking and colorectal cancer in the Women's Health Initiative. *J Natl Cancer Inst* 2007;99:1729–35.
87. Ji BT, Weissfeld JL, Chow WH, et al. Tobacco smoking and colorectal hyperplastic and adenomatous polyps. *Cancer Epidemiol Biomarkers Prev* 2006;15:897–901.
88. US Department of Health and Human Services. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, CDC; 2006.
89. Miller MD, Marty MA, Broadwin R, et al. The association between exposure to environmental tobacco smoke and breast cancer: a review by the California Environmental Protection Agency. *Prev Med* 2007;44:93–106.
90. California Environmental Protection Agency; Air Resources Board. Proposed identification of environmental tobacco smoke as a toxic air contaminant. Tobacco control. surveys and program evaluations from outside UCSF; 2005. Available at <http://repositories.cdlib.org/tc/surveys/CALEPA2005>.

**TABLE 1. Incidence rates\* and percentages† of invasive lung and bronchial cancer, by demographic and tumor characteristics — United States,§ 1999–2004**

Demographic characteristic	Total			Males			Females		
	No.	Rate	(CI) <sup>¶</sup>	No.	Rate	(CI)	No.	Rate	(CI)
<b>Total</b>	<b>1,095,305</b>	<b>69.4</b>	<b>(69.3–69.6)</b>	<b>612,706</b>	<b>89.6</b>	<b>(89.4–89.8)</b>	<b>482,599</b>	<b>54.7</b>	<b>(54.5–54.9)</b>
<b>Age group at diagnosis (yrs)</b>									
<40	8,434	1.0	(0.9–1.0)	4,125	0.9	(0.9–1.0)	4,309	1.0	(1.0–1.0)
40–49	53,780	22.1	(21.9–22.3)	28,775	23.9	(23.7–24.2)	25,005	20.4	(20.1–20.6)
50–59	161,301	88.2	(87.7–88.6)	92,092	103.5	(102.9–104.2)	69,209	73.6	(73.1–74.2)
60–69	304,261	262.5	(261.5–263.4)	174,924	322.0	(320.5–323.6)	129,337	210.0	(208.8–211.1)
70–79	380,185	424.4	(423.0–425.7)	214,777	558.8	(556.5–561.2)	165,408	323.6	(322.1–325.2)
≥80	187,344	346.3	(344.8–347.9)	98,013	524.8	(521.5–528.1)	89,331	253.5	(251.8–255.1)
<b>Race</b>									
White	966,216	69.8	(69.7–70.0)	535,372	88.7	(88.4–88.9)	430,844	56.0	(55.9–56.2)
Black	101,897	74.5	(74.1–75.0)	61,498	111.0	(110.1–112.0)	40,399	50.3	(49.8–50.8)
American Indian/Alaska Native	4,050	43.0	(41.6–44.4)	2,173	52.8	(50.5–55.3)	1,877	35.7	(34.1–37.5)
Asian/Pacific Islander	18,569	38.2	(37.7–38.8)	11,065	52.9	(51.8–53.9)	7,504	27.2	(26.6–27.9)
<b>Ethnicity**</b>									
Hispanic	37,669	37.4	(37.0–37.8)	22,256	51.9	(51.1–52.6)	15,413	26.9	(26.5–27.4)
Non-Hispanic	1,057,636	71.8	(71.7–72.0)	590,450	92.4	(92.1–92.6)	467,186	56.8	(56.6–57.0)
<b>Tumor characteristic††</b>	<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>	
<b>Total</b>	<b>961,879</b>	<b>100.0</b>		<b>541,263</b>	<b>100.0</b>		<b>420,616</b>	<b>100.0</b>	
<b>Histology</b>									
Non–small cell carcinoma	726,432	75.5		414,253	76.5		312,179	74.2	
Adenocarcinoma	350,249	36.4		179,031	33.1		171,218	40.7	
Squamous cell carcinoma	213,248	22.2		140,542	26.0		72,706	17.3	
Non–small cell carcinoma, not otherwise specified	114,840	11.9		66,331	12.3		48,509	11.5	
Large cell carcinoma	48,095	5.0		28,349	5.2		19,746	4.7	
Small cell carcinoma	147,953	15.4		76,604	14.2		71,349	17.0	
Epithelial carcinoma, not otherwise specified	72,064	7.5		42,062	7.8		30,002	7.1	
All other cancers	15,430	1.6		8,344	1.5		7,086	1.7	
<b>Stage§§</b>									
Localized	90,865	18.8		47,030	17.3		43,835	20.6	
Regional	125,361	25.9		71,119	26.2		54,242	25.5	
Distant	225,375	46.5		129,670	47.7		95,705	44.9	
Unknown	43,003	8.9		23,793	8.8		19,210	9.0	
<b>Grade</b>									
Well differentiated	37,062	3.9		17,737	3.3		19,325	4.6	
Moderately differentiated	139,507	14.5		79,352	14.7		60,155	14.3	
Poorly differentiated	276,050	28.7		161,675	29.9		114,375	27.2	
Undifferentiated	91,411	9.5		49,096	9.1		42,315	10.1	
Unknown	417,849	43.4		233,403	43.1		184,446	43.9	

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

¶ 95% confidence interval.

\*\* Ethnicity is not mutually exclusive from race.

†† Includes microscopically confirmed cases only.

§§ Stage at diagnosis according to SEER Summary Stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.



**TABLE 2. Incidence rates\* and percentages† of invasive laryngeal cancer, by demographic and tumor characteristics — United States,§ 1999–2004**

Demographic characteristic	Total			Males			Females		
	No.	Rate	(CI) <sup>¶</sup>	No.	Rate	(CI)	No.	Rate	(CI)
<b>Total</b>	<b>67,618</b>	<b>4.3</b>	<b>(4.2– 4.3)</b>	<b>53,796</b>	<b>7.6</b>	<b>(7.5– 7.6)</b>	<b>13,822</b>	<b>1.6</b>	<b>(1.6– 1.6)</b>
<b>Age group at diagnosis (yrs)</b>									
<40	931	0.1	(0.1– 0.1)	580	0.1	(0.1– 0.1)	351	0.1	(0.1– 0.1)
40–49	6,143	2.5	(2.5– 2.6)	4,704	3.9	(3.8– 4.0)	1,439	1.2	(1.1– 1.2)
50–59	15,828	8.7	(8.5– 8.8)	12,744	14.3	(14.1–14.6)	3,084	3.3	(3.2– 3.4)
60–69	20,569	17.7	(17.5–17.9)	16,426	30.1	(29.7–30.6)	4,143	6.7	(6.5– 6.9)
70–79	17,317	19.3	(19.0–19.6)	13,861	36.0	(35.4–36.6)	3,456	6.8	(6.6– 7.0)
≥80	6,830	12.6	(12.3–12.9)	5,481	29.4	(28.7–30.2)	1,349	3.8	(3.6– 4.0)
<b>Race</b>									
White	56,976	4.1	(4.1– 4.2)	45,241	7.3	(7.2– 7.3)	11,735	1.6	(1.6– 1.6)
Black	9,046	6.3	(6.1– 6.4)	7,234	12.0	(11.8–12.3)	1,812	2.2	(2.1– 2.3)
American Indian/Alaska Native	235	2.2	(1.9– 2.5)	181	3.9	(3.3– 4.5)	54	0.8	(0.6– 1.1)
Asian/Pacific Islander	753	1.5	(1.4– 1.6)	645	2.9	(2.7– 3.2)	108	0.4	(0.3– 0.5)
<b>Ethnicity**</b>									
Hispanic	3,732	3.4	(3.3– 3.5)	3,158	6.5	(6.3– 6.8)	574	0.9	(0.8– 1.0)
Non-Hispanic	63,886	4.3	(4.3– 4.4)	50,638	7.7	(7.6– 7.7)	13,248	1.7	(1.6– 1.7)
<b>Tumor characteristic††</b>	<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>	
<b>Total</b>	<b>65,729</b>	<b>100.0</b>		<b>52,311</b>	<b>100.0</b>		<b>13,418</b>	<b>100.0</b>	
<b>Histology</b>									
Squamous cell carcinoma	63,403	96.5		50,570	96.7		12,833	95.6	
Epithelial carcinoma, not otherwise specified	1,269	1.9		972	1.9		297	2.2	
Adenocarcinoma	413	0.6		275	0.5		138	1.0	
All other cancers	644	1.0		494	0.9		150	1.1	
<b>Stage§§</b>									
Localized	18,570	57.2		15,189	58.7		3,381	51.5	
Regional	8,409	25.9		6,280	24.3		2,129	32.4	
Distant	3,063	9.4		2,531	9.8		532	8.1	
Unknown	2,395	7.4		1,868	7.2		527	8.0	
<b>Grade</b>									
Well differentiated	9,963	15.2		8,319	15.9		1,644	12.3	
Moderately differentiated	30,434	46.3		24,260	46.4		6,174	46.0	
Poorly differentiated	11,709	17.8		8,853	16.9		2,856	21.3	
Undifferentiated	486	0.7		337	0.6		149	1.1	
Unknown	13,137	20.0		10,542	20.2		2,595	19.3	

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

¶ 95% confidence interval.

\*\* Ethnicity is not mutually exclusive from race.

†† Includes microscopically confirmed cases only.

§§ Stage at diagnosis according to SEER Summary Stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.

**TABLE 3. Incidence rates\* and percentages† of invasive oral cavity and pharyngeal cancer, by demographic and tumor characteristics — United States,§ 1999–2004**

Demographic characteristic	Total			Males			Females		
	No.	Rate	(CI) <sup>¶</sup>	No.	Rate	(CI)	No.	Rate	(CI)
<b>Total</b>	<b>169,043</b>	<b>10.6</b>	<b>(10.6–10.7)</b>	<b>115,580</b>	<b>16.0</b>	<b>(15.9–16.1)</b>	<b>53,463</b>	<b>6.1</b>	<b>(6.1–6.2)</b>
<b>Age group at diagnosis (yrs)</b>									
<40	8,167	0.9	(0.9–0.9)	4,724	1.1	(1.0–1.1)	3,443	0.8	(0.8–0.8)
40–49	22,153	9.1	(9.0–9.2)	16,261	13.5	(13.3–13.7)	5,892	4.8	(4.7–4.9)
50–59	41,571	22.8	(22.6–23.0)	31,779	35.8	(35.4–36.2)	9,792	10.5	(10.2–10.7)
60–69	40,374	34.7	(34.4–35.1)	29,050	53.2	(52.6–53.8)	11,324	18.4	(18.0–18.7)
70–79	36,065	40.3	(39.8–40.7)	23,019	59.8	(59.0–60.5)	13,046	25.5	(25.1–26.0)
≥80	20,713	38.3	(37.8–38.8)	10,747	58.3	(57.2–59.4)	9,966	28.0	(27.4–28.5)
<b>Race</b>									
White	145,034	10.5	(10.5–10.6)	99,017	15.8	(15.7–15.9)	46,017	6.1	(6.0–6.1)
Black	16,607	11.0	(10.8–11.2)	11,816	18.1	(17.8–18.5)	4,791	5.6	(5.5–5.8)
American Indian/Alaska Native	706	6.3	(5.8–6.8)	486	9.5	(8.6–10.5)	220	3.7	(3.2–4.2)
Asian/Pacific Islander	4,513	7.7	(7.5–8.0)	2,844	10.6	(10.2–11.0)	1,669	5.3	(5.0–5.6)
<b>Ethnicity**</b>									
Hispanic	8,547	7.2	(7.0–7.4)	5,952	11.1	(10.8–11.4)	2,595	4.1	(3.9–4.2)
Non-Hispanic	160,496	11.0	(10.9–11.0)	109,628	16.5	(16.4–16.6)	50,868	6.3	(6.3–6.4)
<b>Anatomic subsite</b>									
Lip	13,072	0.8	(0.8–0.8)	10,031	1.5	(1.4–1.5)	3,041	0.3	(0.3–0.3)
Oral cavity	80,321	5.1	(5.0–5.1)	51,547	7.1	(7.0–7.2)	28,774	3.3	(3.2–3.3)
Salivary gland	18,773	1.2	(1.2–1.2)	10,926	1.6	(1.6–1.6)	7,847	0.9	(0.9–0.9)
Tonsil	23,494	1.5	(1.5–1.5)	18,462	2.4	(2.4–2.5)	5,032	0.6	(0.6–0.6)
Oropharynx	6,673	0.4	(0.4–0.4)	4,921	0.7	(0.7–0.7)	1,752	0.2	(0.2–0.2)
Nasopharynx	8,978	0.6	(0.6–0.6)	6,082	0.8	(0.8–0.8)	2,896	0.3	(0.3–0.4)
Hypopharynx	12,618	0.8	(0.8–0.8)	9,923	1.4	(1.4–1.4)	2,695	0.3	(0.3–0.3)
Other oral cavity and pharynx	5,114	0.3	(0.3–0.3)	3,688	0.5	(0.5–0.5)	1,426	0.2	(0.2–0.2)
<b>Tumor characteristic††</b>	<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>	
<b>Total</b>	<b>164,977</b>	<b>100.0</b>		<b>112,987</b>	<b>100.0</b>		<b>51,990</b>	<b>100.0</b>	
<b>Histology</b>									
Squamous cell carcinoma	138,104	83.7		98,335	87.0		39,769	76.5	
Adenocarcinoma	7,914	4.8		4,043	3.6		3,871	7.4	
Mucoepidermoid carcinoma	6,311	3.8		3,060	2.7		3,251	6.3	
Epithelial carcinoma, not otherwise specified	5,997	3.6		4,156	3.7		1,841	3.5	
All other cancers	6,651	4.0		3,393	3.0		3,258	6.3	
<b>Stage§§</b>									
Localized	30,405	36.5		18,937	33.2		11,468	43.7	
Regional	38,748	46.6		28,330	49.7		10,418	39.7	
Distant	7,238	8.7		5,185	9.1		2,053	7.8	
Unknown	6,841	8.2		4,546	8.0		2,295	8.7	
<b>Grade</b>									
Well differentiated	23,660	14.3		14,301	12.7		9,359	18.0	
Moderately differentiated	59,313	36.0		40,872	36.2		18,441	35.5	
Poorly differentiated	39,321	23.8		29,221	25.9		10,100	19.4	
Undifferentiated	5,030	3.0		3,543	3.1		1,487	2.9	
Unknown	37,653	22.8		25,050	22.2		12,603	24.2	

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

¶ 95% confidence interval.

\*\* Ethnicity is not mutually exclusive from race.

†† Includes microscopically confirmed cases only.

§§ Stage at diagnosis according to SEER Summary Stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.

**TABLE 4. Incidence rates\* and percentages† of invasive esophageal cancer, by demographic and tumor characteristics — United States,§ 1999–2004**

Demographic characteristic	Total			Males			Females		
	No.	Rate	(CI) <sup>¶</sup>	No.	Rate	(CI)	No.	Rate	(CI)
<b>Total</b>	<b>78,561</b>	<b>5.0</b>	<b>(4.9–5.0)</b>	<b>59,934</b>	<b>8.6</b>	<b>(8.5–8.7)</b>	<b>18,627</b>	<b>2.1</b>	<b>(2.0–2.1)</b>
<b>Age group at diagnosis (yrs)</b>									
<40	822	0.1	(0.1–0.1)	659	0.1	(0.1–0.2)	163	0.0	(0.0–0.0)
40–49	5,150	2.1	(2.1–2.2)	4,308	3.6	(3.5–3.7)	842	0.7	(0.6–0.7)
50–59	14,713	8.1	(7.9–8.2)	12,303	13.8	(13.6–14.1)	2,410	2.6	(2.5–2.7)
60–69	21,208	18.3	(18.0–18.5)	16,958	31.1	(30.7–31.6)	4,250	6.9	(6.7–7.1)
70–79	23,191	25.9	(25.6–26.2)	17,363	45.1	(44.5–45.8)	5,828	11.4	(11.1–11.7)
≥80	13,477	24.9	(24.5–25.3)	8,343	44.9	(43.9–45.8)	5,134	14.4	(14.0–14.8)
<b>Race</b>									
White	66,859	4.8	(4.8–4.9)	51,544	8.4	(8.3–8.5)	15,315	1.9	(1.9–2.0)
Black	9,614	6.9	(6.8–7.0)	6,814	11.7	(11.4–12.0)	2,800	3.5	(3.4–3.6)
American Indian/Alaska Native	299	3.1	(2.7–3.5)	240	5.6	(4.9–6.5)	59	1.2	(0.9–1.5)
Asian/Pacific Islander	1,213	2.4	(2.3–2.6)	901	4.1	(3.8–4.4)	312	1.1	(1.0–1.3)
<b>Ethnicity**</b>									
Hispanic	3,416	3.3	(3.2–3.4)	2,600	5.7	(5.4–5.9)	816	1.5	(1.4–1.6)
Non-Hispanic	75,145	5.1	(5.1–5.1)	57,334	8.8	(8.8–8.9)	17,811	2.1	(2.1–2.1)
<b>Tumor characteristic††</b>	<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>	
<b>Total</b>	<b>74,361</b>	<b>100.0</b>		<b>56,986</b>	<b>100.0</b>		<b>17,375</b>	<b>100.0</b>	
<b>Histology</b>									
Adenocarcinoma	42,131	56.7		35,760	62.8		6,371	36.7	
Squamous cell carcinoma	27,449	36.9		17,761	31.2		9,688	55.8	
Epithelial carcinoma, not otherwise specified	3,903	5.2		2,853	5.0		1,050	6.0	
All other cancers	878	1.2		612	1.1		266	1.5	
<b>Stage§§</b>									
Localized	8,592	23.0		6,400	22.3		2,192	25.4	
Regional	11,095	29.7		8,706	30.4		2,389	27.6	
Distant	10,662	28.6		8,682	30.3		1,980	22.9	
Unknown	6,954	18.6		4,870	17.0		2,084	24.1	
<b>Grade</b>									
Well differentiated	3,714	5.0		2,796	4.9		918	5.3	
Moderately differentiated	24,409	32.8		18,519	32.5		5,890	33.9	
Poorly differentiated	30,624	41.2		23,823	41.8		6,801	39.1	
Undifferentiated	1,513	2.0		1,155	2.0		358	2.1	
Unknown	14,101	19.0		10,693	18.8		3,408	19.6	

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

¶ 95% confidence interval.

\*\* Ethnicity is not mutually exclusive from race.

†† Includes microscopically confirmed cases only.

§§ Stage at diagnosis according to SEER Summary Stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.

**TABLE 5. Incidence rates\* and percentages† of invasive stomach cancer, by demographic and tumor characteristics — United States,§ 1999–2004**

Demographic characteristic	Total			Males			Females		
	No.	Rate	(CI)¶	No.	Rate	(CI)	No.	Rate	(CI)
<b>Total</b>	<b>115,245</b>	<b>7.3</b>	<b>(7.2–7.3)</b>	<b>70,257</b>	<b>10.4</b>	<b>(10.3–10.5)</b>	<b>44,988</b>	<b>4.9</b>	<b>(4.9–5.0)</b>
<b>Age group at diagnosis (yrs)</b>									
<40	3,447	0.4	(0.4–0.4)	1,884	0.4	(0.4–0.4)	1,563	0.4	(0.3–0.4)
40–49	8,357	3.4	(3.4–3.5)	5,228	4.4	(4.2–4.5)	3,129	2.6	(2.5–2.7)
50–59	15,874	8.7	(8.6–8.8)	10,797	12.1	(11.9–12.4)	5,077	5.4	(5.3–5.6)
60–69	24,215	20.9	(20.6–21.1)	16,582	30.5	(30.0–31.0)	7,633	12.4	(12.1–12.7)
70–79	34,049	38.0	(37.6–38.4)	21,239	55.4	(54.6–56.1)	12,810	25.0	(24.6–25.4)
≥80	29,303	54.2	(53.6–54.8)	14,527	79.3	(78.0–80.6)	14,776	41.2	(40.6–41.9)
<b>Race</b>									
White	90,523	6.5	(6.5–6.6)	56,110	9.4	(9.3–9.5)	34,413	4.3	(4.3–4.4)
Black	16,189	12.2	(12.0–12.4)	9,195	17.3	(16.9–17.6)	6,994	8.8	(8.6–9.0)
American Indian/Alaska Native	677	7.1	(6.5–7.6)	404	9.6	(8.6–10.6)	273	5.2	(4.5–5.8)
Asian/Pacific Islander	6,853	14.1	(13.7–14.4)	3,950	18.6	(18.0–19.2)	2,903	10.6	(10.2–11.0)
<b>Ethnicity**</b>									
Hispanic	12,640	11.9	(11.6–12.1)	7,289	15.7	(15.3–16.1)	5,351	9.0	(8.7–9.2)
Non-Hispanic	102,605	7.0	(6.9–7.0)	62,968	10.0	(9.9–10.1)	39,637	4.6	(4.6–4.7)
<b>Tumor characteristic††</b>	<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>	
<b>Total</b>	<b>110,211</b>	<b>100.0</b>		<b>67,769</b>	<b>100.0</b>		<b>42,442</b>	<b>100.0</b>	
<b>Histology</b>									
Adenocarcinoma	99,549	90.3		61,677	91.0		37,872	89.2	
Epithelial carcinoma, not otherwise specified	3,792	3.4		2,287	3.4		1,505	3.5	
Gastrointestinal stromal tumors	3,708	3.4		1,896	2.8		1,812	4.3	
Squamous cell carcinoma	1,039	0.9		750	1.1		289	0.7	
All other cancers	2,123	1.9		1,159	1.7		964	2.3	
<b>Stage§§</b>									
Localized	12,656	22.9		7,371	21.7		5,285	24.8	
Regional	18,016	32.6		11,607	34.2		6,409	30.1	
Distant	16,207	29.3		10,273	30.2		5,934	27.9	
Unknown	8,383	15.2		4,719	13.9		3,664	17.2	
<b>Grade</b>									
Well differentiated	4,802	4.4		2,997	4.4		1,805	4.3	
Moderately differentiated	24,722	22.4		16,519	24.4		8,203	19.3	
Poorly differentiated	55,199	50.1		34,086	50.3		21,113	49.7	
Undifferentiated	2,748	2.5		1,659	2.4		1,089	2.6	
Unknown	22,741	20.6		12,509	18.5		10,232	24.1	

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

¶ 95% confidence interval.

\*\* Ethnicity is not mutually exclusive from race.

†† Includes microscopically confirmed cases only.

§§ Stage at diagnosis according to SEER Summary Stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.



**TABLE 6. Incidence rates\* and percentages† of invasive pancreatic cancer, by demographic and tumor characteristics — United States,§ 1999–2004**

Demographic characteristic	Total			Males			Females		
	No.	Rate	(CI) <sup>¶</sup>	No.	Rate	(CI)	No.	Rate	(CI)
<b>Total</b>	<b>176,409</b>	<b>11.2</b>	<b>(11.1–11.2)</b>	<b>86,793</b>	<b>12.8</b>	<b>(12.7–12.8)</b>	<b>89,616</b>	<b>9.8</b>	<b>(9.8–9.9)</b>
<b>Age group at diagnosis (yrs)</b>									
<40	2,052	0.2	(0.2–0.2)	1,083	0.2	(0.2–0.3)	969	0.2	(0.2–0.2)
40–49	9,347	3.8	(3.8–3.9)	5,552	4.6	(4.5–4.7)	3,795	3.1	(3.0–3.2)
50–59	24,817	13.6	(13.4–13.7)	14,848	16.7	(16.4–17.0)	9,969	10.6	(10.4–10.8)
60–69	39,306	33.9	(33.6–34.2)	21,809	40.1	(39.6–40.6)	17,497	28.4	(28.0–28.8)
70–79	55,572	62.0	(61.5–62.5)	26,836	69.9	(69.1–70.7)	28,736	56.1	(55.4–56.7)
≥80	45,315	83.8	(83.1–84.6)	16,665	90.4	(89.0–91.8)	28,650	80.2	(79.2–81.1)
<b>Race</b>									
White	151,590	10.9	(10.8–10.9)	75,263	12.5	(12.5–12.6)	76,327	9.5	(9.5–9.6)
Black	19,222	14.5	(14.3–14.7)	8,814	16.0	(15.6–16.3)	10,408	13.2	(13.0–13.5)
American Indian/Alaska Native	674	7.2	(6.7–7.8)	315	7.4	(6.5–8.3)	359	7.1	(6.3–7.9)
Asian/Pacific Islander	4,101	8.6	(8.3–8.9)	1,973	9.4	(8.9–9.8)	2,128	8.0	(7.6–8.3)
<b>Ethnicity**</b>									
Hispanic	10,373	10.3	(10.1–10.5)	5,041	11.2	(10.9–11.6)	5,332	9.6	(9.3–9.8)
Non-Hispanic	166,036	11.2	(11.2–11.3)	81,752	12.9	(12.8–13.0)	84,284	9.9	(9.8–9.9)
<b>Tumor characteristic††</b>	<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>	
<b>Total</b>	<b>132,631</b>	<b>100.0</b>		<b>68,261</b>	<b>100.0</b>		<b>64,370</b>	<b>100.0</b>	
<b>Histology</b>									
Adenocarcinoma	101,382	76.4		52,313	76.6		49,069	76.2	
Mucinous adenocarcinoma	7,619	5.7		3,770	5.5		3,849	6.0	
Epithelial carcinoma, not otherwise specified	11,292	8.5		5,923	8.7		5,369	8.3	
Ductal carcinoma	8,073	6.1		4,082	6.0		3,991	6.2	
All other cancers	4,265	3.2		2,173	3.2		2,092	3.2	
<b>Stage§§</b>									
Localized	5,432	8.1		2,535	7.3		2,897	8.9	
Regional	20,210	30.1		10,153	29.4		10,057	30.9	
Distant	34,674	51.6		18,584	53.8		16,090	49.4	
Unknown	6,828	10.2		3,273	9.5		3,555	10.9	
<b>Grade</b>									
Well differentiated	7,991	6.0		3,840	5.6		4,151	6.4	
Moderately differentiated	23,942	18.1		11,929	17.5		12,013	18.7	
Poorly differentiated	27,416	20.7		14,681	21.5		12,735	19.8	
Undifferentiated	1,968	1.5		1,107	1.6		861	1.3	
Unknown	71,314	53.8		36,704	53.8		34,610	53.8	

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

¶ 95% confidence interval.

\*\* Ethnicity is not mutually exclusive from race.

†† Includes microscopically confirmed cases only.

§§ Stage at diagnosis according to SEER Summary Stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.

**TABLE 7. Incidence rates\* and percentages† of invasive kidney and renal pelvis cancer, by demographic and tumor characteristics — United States,§ 1999–2004**

Demographic characteristic	Total			Males			Females		
	No.	Rate	(CI) <sup>¶</sup>	No.	Rate	(CI)	No.	Rate	(CI)
<b>Total</b>	<b>210,331</b>	<b>13.3</b>	<b>(13.2–13.3)</b>	<b>128,712</b>	<b>18.1</b>	<b>(18.0–18.2)</b>	<b>81,619</b>	<b>9.4</b>	<b>(9.3–9.4)</b>
<b>Age group at diagnosis (yrs)</b>									
<40	10,145	1.1	(1.1–1.2)	5,618	1.3	(1.2–1.3)	4,527	1.0	(1.0–1.1)
40–49	22,166	9.1	(9.0–9.3)	14,204	11.8	(11.6–12.0)	7,962	6.5	(6.4–6.6)
50–59	42,797	23.4	(23.2–23.7)	28,341	31.9	(31.5–32.3)	14,456	15.4	(15.2–15.7)
60–69	52,231	45.0	(44.6–45.4)	33,528	61.5	(60.9–62.2)	18,703	30.3	(29.9–30.8)
70–79	54,089	60.4	(59.9–60.9)	32,253	83.9	(82.9–84.8)	21,836	42.7	(42.1–43.3)
≥80	28,903	53.4	(52.8–54.1)	14,768	79.1	(77.8–80.4)	14,135	39.9	(39.3–40.6)
<b>Race</b>									
White	184,043	13.4	(13.3–13.4)	112,909	18.2	(18.1–18.3)	71,134	9.4	(9.4–9.5)
Black	19,749	13.6	(13.4–13.8)	11,746	19.2	(18.8–19.5)	8,003	9.6	(9.4–9.8)
American Indian/Alaska Native	1,362	12.4	(11.7–13.2)	793	15.8	(14.6–17.1)	569	9.6	(8.8–10.5)
Asian/Pacific Islander	3,221	6.0	(5.8–6.2)	2,018	8.4	(8.0–8.8)	1,203	4.1	(3.9–4.3)
<b>Ethnicity**</b>									
Hispanic	15,498	13.1	(12.9–13.3)	9,242	17.3	(16.9–17.7)	6,256	9.7	(9.5–10.0)
Non-Hispanic	194,833	13.3	(13.3–13.4)	119,470	18.2	(18.1–18.3)	75,363	9.3	(9.3–9.4)
<b>Tumor characteristic††</b>	<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>	
<b>Total</b>	<b>190,088</b>	<b>100.0</b>		<b>117,443</b>	<b>100.0</b>		<b>72,645</b>	<b>100.0</b>	
<b>Histology</b>									
Adenocarcinoma	165,586	87.1		103,523	88.1		62,063	85.4	
Renal cell carcinoma	101,996	53.7		63,482	54.1		38,514	53.0	
Clear cell adenocarcinoma	39,596	20.8		23,950	20.4		15,646	21.5	
Transitional cell carcinoma	16,628	8.7		9,510	8.1		7,118	9.8	
Epithelial carcinoma, not otherwise specified	2,144	1.1		1,312	1.1		832	1.1	
All other cancers	5,730	3.0		3,098	2.6		2,632	3.6	
<b>Stage§§</b>									
Localized	61,706	63.2		37,179	61.5		24,527	65.9	
Regional	16,766	17.2		10,835	17.9		5,931	15.9	
Distant	15,073	15.4		9,837	16.3		5,236	14.1	
Unknown	4,127	4.2		2,588	4.3		1,539	4.1	
<b>Grade</b>									
Well differentiated	21,466	11.3		11,590	9.9		9,876	13.6	
Moderately differentiated	59,615	31.4		36,994	31.5		22,621	31.1	
Poorly differentiated	35,721	18.8		23,115	19.7		12,606	17.4	
Undifferentiated	10,371	5.5		6,493	5.5		3,878	5.3	
Unknown	62,915	33.1		39,251	33.4		23,664	32.6	

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

¶ 95% confidence interval.

\*\* Ethnicity is not mutually exclusive from race.

†† Includes microscopically confirmed cases only.

§§ Stage at diagnosis according to SEER Summary Stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.

**TABLE 8. Incidence rates\* and percentages† of in situ and invasive urinary bladder cancer, by demographic and tumor characteristics — United States,§ 1999–2004**

Demographic characteristic	Total			Males			Females		
	No.	Rate	(CI) <sup>¶</sup>	No.	Rate	(CI)	No.	Rate	(CI)
<b>Total</b>	<b>342,515</b>	<b>21.7</b>	<b>(21.6–21.8)</b>	<b>254,213</b>	<b>38.2</b>	<b>(38.1–38.4)</b>	<b>88,302</b>	<b>9.7</b>	<b>(9.7– 9.8)</b>
<b>Age group at diagnosis (yrs)</b>									
<40	4,387	0.5	(0.5– 0.5)	3,017	0.7	(0.7– 0.7)	1,370	0.3	(0.3– 0.3)
40–49	14,685	6.0	(5.9– 6.1)	10,881	9.1	(8.9– 9.2)	3,804	3.1	(3.0– 3.2)
50–59	42,393	23.2	(23.0–23.4)	32,261	36.3	(35.9–36.7)	10,132	10.8	(10.6–11.0)
60–69	77,826	67.2	(66.7–67.7)	59,665	110.0	(109.1–110.9)	18,161	29.5	(29.1–29.9)
70–79	117,477	131.1	(130.4–131.9)	89,211	232.6	(231.1–234.1)	28,266	55.2	(54.5–55.8)
≥80	85,747	158.6	(157.5–159.7)	59,178	321.7	(319.1–324.3)	26,569	74.5	(73.6–75.4)
<b>Race</b>									
White	318,380	22.9	(22.8–23.0)	237,650	40.3	(40.1–40.4)	80,730	10.2	(10.1–10.2)
Black	14,806	11.4	(11.2–11.6)	9,471	18.6	(18.2–19.0)	5,335	6.8	(6.6– 7.0)
American Indian/Alaska Native	678	7.5	(6.9– 8.1)	497	12.7	(11.5–14.0)	181	3.6	(3.1– 4.2)
Asian/Pacific Islander	4,068	8.8	(8.5– 9.0)	3,070	15.3	(14.8–15.9)	998	3.8	(3.6– 4.1)
<b>Ethnicity**</b>									
Hispanic	12,112	12.3	(12.1–12.5)	8,918	21.5	(21.0–22.0)	3,194	5.7	(5.5– 5.9)
Non-Hispanic	330,403	22.4	(22.3–22.4)	245,295	39.4	(39.2–39.6)	85,108	10.0	(10.0–10.1)
<b>Tumor characteristic††</b>	<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>		<b>No.</b>	<b>%</b>	
<b>Total</b>	<b>336,502</b>	<b>100.0</b>		<b>250,362</b>	<b>100.0</b>		<b>86,140</b>	<b>100.0</b>	
<b>Histology</b>									
Transitional cell carcinoma	316,327	94.0		237,091	94.7		79,236	92.0	
Squamous cell carcinoma	7,749	2.3		4,726	1.9		3,023	3.5	
Epithelial carcinoma, not otherwise specified	6,139	1.8		4,369	1.7		1,770	2.1	
Adenocarcinoma	4,187	1.2		2,772	1.1		1,415	1.6	
All other cancers	2,100	0.6		1,404	0.6		696	0.8	
<b>Stage§§</b>									
Localized	164,433	99.5		122,496	99.5		41,937	99.4	
Regional	563	0.3		415	0.3		148	0.4	
Distant	209	0.1		146	0.1		63	0.1	
Unknown	137	0.1		100	0.1		37	0.1	
<b>Grade</b>									
Well differentiated	60,359	17.9		44,072	17.6		16,287	18.9	
Moderately differentiated	105,352	31.3		78,777	31.5		26,575	30.9	
Poorly differentiated	95,001	28.2		70,668	28.2		24,333	28.2	
Undifferentiated	35,080	10.4		26,295	10.5		8,785	10.2	
Unknown	40,710	12.1		30,550	12.2		10,160	11.8	

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

¶ 95% confidence interval.

\*\* Ethnicity is not mutually exclusive from race.

†† Includes microscopically confirmed cases only.

§§ Stage at diagnosis according to SEER Summary Stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs. Localized stage includes in situ cases.

**TABLE 9. Incidence rates\* and percentages† of invasive cervical cancer, by demographic and tumor characteristics — United States,‡ 1999–2004**

Demographic characteristic	No.	Rate	(CI¶)
<b>Total</b>	<b>72,878</b>	<b>8.9</b>	<b>(8.8–8.9)</b>
<b>Age group at diagnosis (yrs)</b>			
<40	20,068	4.5	(4.5–4.6)
40–49	18,981	15.6	(15.4–15.8)
50–59	13,408	14.4	(14.1–14.6)
60–69	9,183	14.9	(14.6–15.2)
70–79	6,805	13.3	(13.0–13.7)
≥80	4,433	12.5	(12.1–12.9)
<b>Race</b>			
White	57,167	8.4	(8.3–8.5)
Black	11,097	12.5	(12.3–12.7)
American Indian/Alaska Native	486	6.8	(6.2–7.5)
Asian/Pacific Islander	2,763	8.2	(7.9–8.5)
<b>Ethnicity**</b>			
Hispanic	11,293	14.0	(13.8–14.3)
Non-Hispanic	61,585	8.4	(8.3–8.4)
<b>Tumor characteristic††</b>			
	<b>No.</b>	<b>%</b>	
<b>Total</b>	<b>71,124</b>	<b>100.0</b>	
<b>Histology</b>			
Squamous cell carcinoma	50,322	70.8	
Adenocarcinoma	16,175	22.7	
Epithelial carcinoma, not otherwise specified	3,215	4.5	
All other cancers	1,412	2.0	
<b>Stage§§</b>			
Localized	17,723	50.7	
Regional	11,427	32.7	
Distant	3,319	9.5	
Unknown	2,488	7.1	
<b>Grade</b>			
Well differentiated	6,163	8.7	
Moderately differentiated	20,151	28.3	
Poorly differentiated	20,247	28.5	
Undifferentiated	1,474	2.1	
Unknown	23,092	32.5	

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. *United States cancer statistics: 2004 incidence and mortality*. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

¶ 95% confidence interval.

\*\* Ethnicity is not mutually exclusive from race.

†† Includes microscopically confirmed cases only.

§§ Stage at diagnosis according to SEER Summary Stage 2000 for cases diagnosed during 2001–2003. Localized: cancer that is confined to the primary site; regional: cancer that has spread directly beyond the primary site or to regional lymph nodes; distant: cancer that has spread to other organs.



**TABLE 10. Incidence rates\* and percentages† of acute myelogenous leukemia,§ by demographic characteristics — United States,¶ 1999–2004**

Demographic characteristic	Total			Males			Females		
	No.	Rate	(CI)**	No.	Rate	(CI)	No.	Rate	(CI)
<b>Total</b>	<b>62,708</b>	<b>4.0</b>	<b>(3.9–4.0)</b>	<b>34,009</b>	<b>4.9</b>	<b>(4.9–5.0)</b>	<b>28,699</b>	<b>3.3</b>	<b>(3.2–3.3)</b>
<b>Age group at diagnosis (yrs)</b>									
<40	9,123	1.0	(1.0–1.0)	4,728	1.0	(1.0–1.1)	4,395	1.0	(1.0–1.0)
40–49	5,357	2.2	(2.2–2.3)	2,715	2.3	(2.2–2.4)	2,642	2.2	(2.1–2.2)
50–59	7,881	4.3	(4.2–4.4)	4,249	4.8	(4.6–4.9)	3,632	3.9	(3.8–4.0)
60–69	11,333	9.8	(9.6–10.0)	6,644	12.2	(11.9–12.5)	4,689	7.6	(7.4–7.8)
70–79	16,568	18.5	(18.2–18.8)	9,557	24.9	(24.4–25.4)	7,011	13.7	(13.4–14.0)
≥80	12,446	23.0	(22.6–23.4)	6,116	33.1	(32.2–33.9)	6,330	17.8	(17.4–18.2)
<b>Race</b>									
White	55,553	4.1	(4.0–4.1)	30,346	5.0	(5.0–5.1)	25,207	3.4	(3.3–3.4)
Black	4,721	3.2	(3.1–3.3)	2,310	3.7	(3.6–3.9)	2,411	2.8	(2.7–2.9)
American Indian/Alaska Native	251	2.1	(1.8–2.4)	127	2.4	(2.0–2.9)	124	1.9	(1.6–2.3)
Asian/Pacific Islander	1,741	3.1	(2.9–3.3)	979	4.0	(3.7–4.2)	762	2.4	(2.3–2.6)
<b>Ethnicity††</b>									
Hispanic	4,680	3.4	(3.3–3.5)	2,436	4.0	(3.8–4.2)	2,244	3.0	(2.9–3.2)
Non-Hispanic	58,028	4.0	(4.0–4.0)	31,573	5.0	(4.9–5.0)	26,455	3.3	(3.3–3.3)

\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† New cases diagnosed.

§ Includes cases diagnosed as acute myeloid leukemia and acute monocytic leukemia.

¶ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.

\*\* 95% confidence interval.

†† Ethnicity is not mutually exclusive from race.

**TABLE 11. Estimated annual percentage change (EAPC)\* in incidence rates† of tobacco-related cancers, by cancer site and sex — United States,§ 1999–2004**

Cancer site	Total		Males		Females	
	EAPC	p value¶	EAPC	p value	EAPC	p value
Lung and bronchus	-0.91	0.02	-1.90	0.001	0.18	0.53
Larynx	-2.75	<0.001	-3.04	<0.001	-2.27	0.04
Oral cavity and pharynx	-0.58	0.009	-0.45	0.06	-1.30	0.01
Esophagus	0.03	0.90	0.26	0.40	-1.16	0.05
Stomach	-1.62	<0.001	-2.03	<0.001	-1.20	0.02
Pancreas	0.28	0.17	0.26	0.23	0.25	0.32
Kidney and renal pelvis	3.14	<0.001	2.90	<0.001	3.23	<0.001
Urinary bladder	-0.39	0.001	-0.65	<0.001	-0.48	0.04
Cervix	-4.10	<0.001	—	—	-4.10	0.001
Acute myeloid leukemia	-0.95	0.21	-1.28	0.16	-0.74	0.37

\* Calculated by weighted least squares method.

† New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

§ Data are from 40 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results (SEER) statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for all years (1999–2004) (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). States not meeting these criteria were excluded.


¶ p<0.05 was considered statistically significant.

**TABLE 12. Average relative risks for tobacco-related cancers**

Cancer site	Average relative risk	Cancer site	Average relative risk
Lung and bronchus	15.0–30.0	Pancreas	2.0–4.0
Larynx	10.0	Kidney and renal pelvis	1.5–2.0
Oral cavity and pharynx	4.0–5.0	Urinary bladder	3.0
Esophagus	1.5–2.5	Cervix	1.5–2.5
Stomach	1.5–2.0	Acute myelogenous leukemia	1.5–2.0

**SOURCE:** Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological evidence. *J Natl Cancer Inst* 2004;96:99–106.

**FIGURE 1. Incidence rates\* for male lung and bronchial cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 66.0; Midwest: 88.6; Northeast: 81.0; South: 97.9. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics for 2004* (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 2. Incidence rates\* for female lung and bronchial cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 48.1; Midwest: 55.7; Northeast: 55.3; South: 56.4. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics for 2004* (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 3. Incidence rates\* for male laryngeal cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

†West: 4.8; Midwest: 7.3; Northeast: 7.4; South: 8.4. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 4. Incidence rates\* for female laryngeal cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

†West: 1.1; Midwest: 1.7; Northeast: 1.6; South: 1.7. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 5. Incidence rates\* for male oral cavity and pharyngeal cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 14.7; Midwest: 15.6; Northeast: 15.0; South: 16.9. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 6. Incidence rates\* for female oral cavity and pharyngeal cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 5.8; Midwest: 5.7; Northeast: 5.8; South: 6.0. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 7. Incidence rates\* for male esophageal cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 7.8; Midwest: 9.5; Northeast: 9.8; South: 8.2. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 8. Incidence rates\* for female esophageal cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 1.8; Midwest: 2.2; Northeast: 2.2; South: 1.9. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.



**FIGURE 9. Incidence rates\* for male stomach cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 9.9; Midwest: 9.0; Northeast: 11.7; South: 9.0. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 10. Incidence rates\* for female stomach cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 5.1; Midwest: 3.9; Northeast: 5.6; South: 4.5. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 11. Incidence rates\* for male pancreatic cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 11.7; Midwest: 12.9; Northeast: 13.8; South: 12.7. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 12. Incidence rates\* for female pancreatic cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 9.6; Midwest: 9.2; Northeast: 10.9; South: 9.5. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 13. Incidence rates\* for male kidney and renal pelvis cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 17.0; Midwest: 19.3; Northeast: 20.4; South: 19.7. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 14. Incidence rates\* for female kidney and renal pelvis cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† West: 8.5; Midwest: 10.7; Northeast: 10.3; South: 10.3. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 15. Incidence rates\* for male urinary bladder cancer,† by state and U.S. Census region§ — United States,¶ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

†Includes in situ and invasive cases.

§ *West: 35.4; Midwest: 37.6; Northeast: 44.7; South: 34.1. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)*

¶ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics for 2004* (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 16. Incidence rates\* for female urinary bladder cancer,† by state and U.S. Census region§ — United States,¶ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

†Includes in situ and invasive cases.

§ *West: 8.8; Midwest: 9.3; Northeast: 11.8; South: 8.8. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)*

¶ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics for 2004* (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 17. Incidence rates\* for cervical cancer, by state and U.S. Census region† — United States,§ 2004**




\*New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† *West: 7.4; Midwest: 7.4; Northeast: 8.0; South: 8.6.* (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

§Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics for 2004* (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.



**FIGURE 18. Incidence rates\* for male acute myelogenous leukemia,† by state and U.S. Census region§ — United States,¶ 2004**




\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† Includes cases diagnosed as acute myeloid leukemia and acute monocytic leukemia.

§ West: 4.3; Midwest: 4.9; Northeast: 5.0; South: 4.5. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

¶ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

**FIGURE 19. Incidence rates\* for female acute myelogenous leukemia,† by state and U.S. Census region§ — United States,¶ 2004**



\* New cases diagnosed per 100,000 persons, age adjusted to the 2000 U.S. standard population.

† Includes cases diagnosed as acute myeloid leukemia and acute monocytic leukemia.

§ West: 2.9; Midwest: 3.4; Northeast: 3.4; South: 3.0. (West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin; Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Virginia, West Virginia, Tennessee, and Texas.)

¶ Data are from 45 National Program of Cancer Registries and five Surveillance, Epidemiology, and End Results statewide cancer registries that met data-quality criteria for all invasive cancer sites combined according to *United States Cancer Statistics* for 2004 (US Cancer Statistics Working Group. United States cancer statistics: 2004 incidence and mortality. Atlanta, GA: US Department of Health and Human Services, CDC, National Cancer Institute; 2007. Available at <http://apps.nccd.cdc.gov/uscs>). Maryland was excluded because it did not meet these criteria.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, send an e-mail message to [listserv@listserv.cdc.gov](mailto:listserv@listserv.cdc.gov). The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's Internet server at <http://www.cdc.gov/mmwr> or from CDC's file transfer protocol server at <ftp://ftp.cdc.gov/pub/publications/mmwr>. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to [mmwrq@cdc.gov](mailto:mmwrq@cdc.gov).

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.